Compositions and methods for recombinant nerve growth factor

Abstract

Provided are nerve growth factor (NGF) variants with improved in vivo stability, methods for producing and purifying NGF variants, and therapeutic uses. [Solution] A polypeptide is provided that includes: (i) a first portion that includes a full-length nerve growth factor (NGF) polypeptide sequence, or a biologically active fragment thereof; and (ii) a second portion that includes an additional polypeptide that increases the half-life of the NGF polypeptide sequence, or a biologically active fragment thereof, in the human bloodstream.

Description

[Technical field]

[0001] Related Applications This application claims the benefit of priority to U.S. Provisional Patent Application No. 62 / 457,499, filed February 10, 2017, which is incorporated by reference in its entirety. [Background technology]

[0002] Nerve growth factor (NGF) was first isolated from a mouse sarcoma by Nobel Prize winner Rita Levi-Montalcini in 1953 and is the first neurotrophic factor discovered. NGF primarily regulates the survival, differentiation and proliferation of sympathetic and sensory neurons from the neural crest. It also plays an important role in the recovery of neurological function and in the process of nerve regeneration.

[0003] NGF is abundant in various sources, with mouse submandibular glands being one of the most intensively studied sources of NGF. Other sources include snake venom, bull seminal vesicles, guinea pig prostate, and human placenta. Of these sources, the gene sequence of mouse NGF is the most highly homologous (>90%) to the human sequence, and therefore mouse NGF isolated from the submandibular gland and human NGF from the placenta are used in clinical applications, primarily for the treatment of optic nerve injury. Additional conditions responsive to treatment with NGF include toxic neuropathy, peripheral neuropathy, facial neuropathy, etc.

[0004] Currently, mouse NGF is administered by intramuscular injection. Due to the short half-life of mouse NGF, daily injections (30 μg mouse NGF) are required over a 4-week period. The main adverse effect is local pain resulting from multiple injections over the course of treatment. Preliminary pharmacokinetic data indicate that human NGF exhibits a similar in vivo half-life to mouse NGF and therefore will likely require a similar drug administration frequency in clinical use, i.e., daily injections. However, daily injections are very inconvenient and uncomfortable for patients. Summary of the Invention [Problem to be solved by the invention]

[0005] Thus, there is a need for improved therapeutic forms of human NGF (NGF) that can be more easily administered. [Means for solving the problem]

[0006] The present invention relates, in part, to a long-lasting recombinant human nerve growth factor (rhNGF) that has a longer half-life in patients. Specifically, compared to unmodified rhNGF, the long-lasting nerve growth factor exhibits similar biological activity, but has a substantially longer in vivo half-life as demonstrated in animal studies. The NGF variant polypeptides described herein include additional polypeptide moieties in addition to the NGF moiety. In some embodiments, the additional polypeptide moieties increase the in vivo stability (e.g., half-life) of the NGF moiety. In some embodiments, such additional polypeptides include human chorionic gonadotropin (hCG) or biologically active fragments thereof. In some preferred embodiments, such additional polypeptides include at least the carboxy terminal portion (CTP) of hCG.

[0007] In one aspect, the present invention provides a method for producing (i) a first portion comprising a full-length nerve growth factor (NGF) polypeptide sequence or a biologically active fragment thereof; and (ii) a second portion comprising an additional polypeptide that increases the half-life of the NGF polypeptide sequence or a biologically active fragment thereof. The present invention provides a polypeptide comprising:

[0008] In some embodiments, the first portion of the polypeptide described herein comprises a full-length NGF polypeptide sequence. In other embodiments, the first portion of the polypeptide described herein comprises a fragment that has the biological activity of NGF.

[0009] The polypeptides described herein may have a mammalian origin. For example, such a polypeptide, or a first portion thereof and / or a second portion thereof, comprises a mammalian sequence, such as a human or mouse sequence. In some embodiments, the first portion of the polypeptide described herein comprises a human NGF sequence. Such a human NGF sequence may be at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to SEQ ID NO:5. In some embodiments, the human NGF sequence is at least 70% identical to SEQ ID NO:5. In some embodiments, the human NGF sequence is at least 80% identical to SEQ ID NO:5. In some embodiments, the human NGF sequence is at least 90% identical to SEQ ID NO:5. In some embodiments, the human NGF sequence is at least 95% identical to SEQ ID NO:5. In some embodiments, the human NGF sequence is at least 99% identical to SEQ ID NO:5. In some embodiments, the human NGF sequence is SEQ ID NO:5. In some embodiments, the human NGF sequence is encoded by a polynucleotide that specifically hybridizes under stringent conditions to a polynucleotide encoding a polypeptide having a sequence complementary to SEQ ID NO:5.

[0010] In some embodiments, the first portion of the polypeptide described herein is capable of binding to at least one binding partner of NGF, optionally wherein the at least one binding partner of NGF is tropomyosin receptor kinase A (TrkA) or low affinity NGF receptor (LNGFR / p75NTR). In some embodiments, the first portion of the polypeptide described herein comprises a fragment having a biological activity of NGF, wherein such biological activity is measured by its interaction with at least one of NGF binding partners, such as TrkA and LNGFR / p75NTR. In some embodiments, the first portion of the polypeptide described herein comprises amino acid residues 122 to 241 of SEQ ID NO:5.

[0011] In some embodiments, the second portion of the polypeptide described herein comprises full-length human chorionic gonadotropin (HCG), or a biologically active fragment thereof.

[0012] In some embodiments, the second portion of the polypeptide described herein comprises a human HCG sequence, such as one of SEQ ID NOs: 10-12. In some embodiments, the second portion comprises the carboxy terminal portion (CTP) of HCG. In some embodiments, the second portion of the polypeptide described herein comprises at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity to SEQ ID NO: 13. In some embodiments, the second portion is at least 70% identical to SEQ ID NO: 13. In some embodiments, the second portion is at least 75% identical to SEQ ID NO: 13. In some embodiments, the second portion is at least 80% identical to SEQ ID NO: 13. In some embodiments, the second portion is at least 90% identical to SEQ ID NO: 13. In some embodiments, the second portion is at least 95% identical to SEQ ID NO: 13. In some embodiments, the second portion is at least 99% identical to SEQ ID NO: 13. In some embodiments, the second portion comprises SEQ ID NO: 13. In some embodiments, the second portion is encoded by a polynucleotide that specifically hybridizes under stringent conditions to a polynucleotide encoding a polypeptide having a sequence complementary to SEQ ID NO:13.

[0013] In some embodiments, the second portion of a polypeptide described herein comprises at least one glycosylation site.

[0014] In some embodiments, the polypeptides described herein are fusion proteins. For example, the first and second portions of the polypeptide may be fused to each other with or without a linker (e.g., a peptide linker). The first portion may be fused to the N-terminus of the second portion or to the C-terminus of the second portion. Multiple copies of the first and / or second portion may be fused to each other.

[0015] In some embodiments, the polypeptides described herein comprise an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to SEQ ID NO: 2 or 3. In some embodiments, the polypeptide sequence is at least 70% identical to SEQ ID NO: 2 or 3. In some embodiments, the polypeptide sequence is at least 75% identical to SEQ ID NO: 2 or 3. In some embodiments, the polypeptide sequence is at least 80% identical to SEQ ID NO: 2 or 3. In some embodiments, the polypeptide sequence is at least 90% identical to SEQ ID NO: 2 or 3. In some embodiments, the polypeptide sequence is at least 95% identical to SEQ ID NO: 2 or 3. In some embodiments, the polypeptide sequence is at least 99% identical to SEQ ID NO: 2 or 3. In some embodiments, the polypeptide sequence comprises SEQ ID NO: 2 or 3. In some embodiments, the polypeptide is encoded by a polynucleotide that specifically hybridizes under stringent conditions to a polynucleotide encoding a polypeptide having a sequence complementary to SEQ ID NO: 2 or 3.

[0016] In some embodiments, the polypeptide described herein exhibits an increased half-life in vivo compared to its first portion.For example, the polypeptide may have an in vivo half-life, for example in humans, that is at least 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0 times or more than the in vivo half-life of its first portion (i.e., NGF polypeptide sequence) alone.In some embodiments, the polypeptide has an in vivo half-life that is at least 2.5 times the in vivo half-life of the NGF polypeptide sequence alone.

[0017] In some embodiments, the polypeptide described herein, or the first or second portion thereof, further comprises a label, such as a purification label and / or tag (e.g., GST, FLAG, hexahis (His6), etc.), and / or a fluorescent tag.

[0018] In another aspect, the present invention provides a polynucleotide encoding a polypeptide as described herein. For example, such a polynucleotide may comprise a nucleic acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to SEQ ID NO:1. In some embodiments, the polynucleotide sequence is at least 70% identical to SEQ ID NO:1. In some embodiments, the polynucleotide sequence is at least 80% identical to SEQ ID NO:1. In some embodiments, the polynucleotide sequence is at least 90% identical to SEQ ID NO:1. In some embodiments, the polynucleotide sequence is at least 95% identical to SEQ ID NO:1. In some embodiments, the polynucleotide sequence is at least 99% identical to SEQ ID NO:1. In some embodiments, the polynucleotide sequence comprises SEQ ID NO:1. In some embodiments, the polynucleotide sequence specifically hybridizes under stringent conditions to a sequence complementary to SEQ ID NO:1. In some embodiments, the polynucleotides described herein further comprise a detection label, such as a purification label and / or tag (e.g., GST, FLAG, hexahis (His6), etc.), and / or a fluorescent tag, etc. In some embodiments, stringent conditions comprise overnight hybridization at 65°C in 50% v / v formamide, 5 x SSC, 2% w / v blocking agent, 0.1% N-lauroyl sarcosine, 0.3% SDS, and a wash in 5 x SSC at about 65°C.

[0019] In another aspect, the present invention provides an expression vector capable of expressing the polypeptides and / or polynucleotides described herein. Such expression vectors may be plasmids, cosmids, viral vectors, etc., with or without genetic modification.

[0020] In another aspect, the present invention provides a host cell comprising an expression vector, polypeptide or polynucleotide described herein. Such a host cell can be a bacterial cell, a yeast cell, an insect cell, a chicken cell, or a mammalian cell (such as a CHO, Hela, HT293, or other cell). In some embodiments, the host cell described herein is immortalized.

[0021] In another aspect, the present invention provides a method for producing a pharmaceutical composition comprising: (i) culturing a host cell described herein in a cell culture medium; and (ii) expressing a polypeptide as described herein The present invention provides a method comprising: In some embodiments, the method further comprises: (iii) purifying the polypeptide described herein from the cell culture medium. Includes. By these exemplary methods, the polypeptides described herein can be produced, isolated, and ultimately purified for further use.

[0022] In another aspect, the present invention also provides compositions comprising the polypeptides, polynucleotides, expression vectors and / or host cells described herein, In some such embodiments, the composition is a pharmaceutical composition further comprising a pharma- ceutically acceptable carrier.

[0023] In another aspect, the present invention provides a method of treating a disease or injury associated with a deficiency and / or defect in nerve growth factor (NGF), comprising administering to a subject a polypeptide, composition or pharmaceutical composition as described herein. Such a disease or injury may be any one of the neurological disorders described herein, such as neurodegeneration. In some embodiments, the method further comprises administering to the subject an additional agent and / or therapy for treating the disease or injury.

[0024] In another aspect, the present invention provides a method for promoting the growth and / or proliferation of neurons, the method comprising administering to a subject a polypeptide, composition or pharmaceutical composition described herein.

[0025] In some embodiments, the subject is a mammal, such as a non-human mammal (e.g., mouse, dog, cat, etc.) or a human. In a preferred embodiment, the subject is a human. [Brief description of the drawings]

[0026] [Figure 1] 1 shows an outline of the structure of the pCI-neo / NGF-CTP plasmid. [Diagram 2] 1 shows gel electrophoresis of purified rhNGF-CTP protein. [Diagram 3] 1 shows rat plasma concentration profiles of rhNGF and rhNGF-CTP in a pharmacokinetic study after intravenous injection. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0027] The present invention relates, in part, to the discovery of nerve growth factor (NGF) variants, particularly NGF variants that include a full-length NGF sequence or a biologically active fragment thereof and another polypeptide, which may be more stable (e.g., have a longer half-life) in vitro, ex vivo, and / or in vivo than wild-type NGF protein.

[0028] Thus, polypeptides, polynucleotides, and compositions of NGF variants that maintain at least some or all of the wild-type NGF activity are provided. In some embodiments, the NGF variants comprise a full-length NGF sequence, or a biologically active fragment thereof. In some embodiments, the NGF variants comprise another polypeptide, preferably a heterologous polypeptide, for example, to form a fusion protein. For example, the NGF portion and the heterologous polypeptide portion of the NGF variants described herein may be fused to each other with or without a linker. In some embodiments, the NGF portion is fused to the N-terminus of the heterologous polypeptide. In other embodiments, the NGF portion is fused to the C-terminus of the heterologous polypeptide. The amino acid sequence of the NGF portion of the NGF variants described herein may be derived from the wild-type NGF sequence or derived by substitution, insertion, or deletion of one or more amino acids of a parent NGF amino acid sequence (such as a wild-type NGF sequence). The NGF variants may retain at least 70% amino acid sequence identity with the wild-type or parent NGF molecule from which they are derived. Useful amounts of these NGF variants can be prepared using recombinant DNA techniques.

[0029] Another aspect of the invention provides recombinant nucleic acids encoding the NGF variants, as well as expression vectors and host cells containing these nucleic acids.

[0030] Another aspect of the invention provides methods for producing NGF variants, including methods using the nucleic acids, vectors, and host cells of the invention. In some embodiments, a host cell transformed with an expression vector containing a nucleic acid encoding an NGF variant is cultured to allow expression of the nucleic acid to produce a recombinant NGF variant.

[0031] Additionally provided are methods and compositions, using the NGF variants and related therapeutic agents described herein, for treating a neurodegenerative disease or disorder (e.g., a neurological disorder, such as neurodegeneration) in a subject.

[0032] Other advantages and aspects of the present invention will become apparent from the following detailed description, drawings and claims.

[0033] I. Definition The articles "a" and "an" are used herein to refer to one or to more than one (i.e., to at least one) of the grammatical object of the article. By way of example, "an element" means one element or more than one element.

[0034] The term "administering" is intended to include routes of administration that allow an agent (such as a polypeptide and / or composition described herein) to perform its intended function. Examples of routes of administration for physical treatment that may be used include injection (subcutaneous, intravenous, parenteral, intraperitoneal, intrathecal, etc.), oral, inhalation, and transdermal routes. The injection may be a bolus injection or a continuous infusion. Depending on the route of administration, the agent may be coated with or dispensed into a selected material to protect it from natural conditions that may adversely affect its ability to perform its intended function. The agent may be administered alone or in combination with a pharma- ceutically acceptable carrier. The agent may also be administered as a prodrug, which is converted to its active form in vivo. In some embodiments, the agent is administered orally. In other embodiments, the agent is administered by an injection route as described herein.

[0035] The term "increased / decreased amount" or "increased / decreased level" refers to an increase or decrease in the absolute and / or relative amount and / or value of a molecule (e.g., NGF) in a subject when compared to the amount and / or value of the same molecule in a previous same subject and / or in normal and / or control subjects.

[0036] The amount of a molecule (e.g., NGF) in a subject is "significantly" higher or lower than the normal amount of the molecule if the amount of the molecule is higher or lower than the normal level, respectively, by an amount greater than the standard error of the assay used to assess the amount, and preferably at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 150%, 200%, 300%, 350%, 400%, 500%, 600%, 700%, 800%, 900%, 1000% or more than the amount. Alternatively, the amount of a molecule in a subject may be considered "significantly" higher or lower than the normal amount if the amount is at least about 2-fold, preferably at least about 3-fold, 4-fold, or 5-fold higher or lower, respectively, than the normal amount of the molecule. Such "significance" may also be applied to any other measured parameters described herein for expression, inhibition, cytotoxicity, cell proliferation, etc.

[0037] The term "coding region" refers to the region of a nucleotide sequence that contains codons that are translated into amino acid residues, while the term "non-coding region" refers to the regions of a nucleotide sequence that are not translated into amino acids (e.g., the 5' and 3' untranslated regions).

[0038] The term "complementarity" refers to the broad concept of sequence complementarity between regions of two nucleic acid strands or between two regions of the same nucleic acid strand. It is known that an adenine residue in a first nucleic acid region can form specific hydrogen bonds ("base pairing") with a residue in a second nucleic acid region that is antiparallel to the first region if that residue is thymine or uracil. Similarly, it is known that a cytosine residue in a first nucleic acid strand can base pair with a residue in a second nucleic acid strand that is antiparallel to the first strand if that residue is guanine. A first region of a nucleic acid is complementary to a second region of the same or a different nucleic acid if the two regions are arranged in an antiparallel manner and at least one nucleotide residue in the first region is capable of base pairing with a residue in the second region. Preferably, the first region comprises a first portion and the second region comprises a second portion, whereby the first portion and the second portion are arranged in an antiparallel manner and at least about 50%, preferably at least about 75%, at least about 90%, or at least about 95% of the nucleotide residues of the first portion are capable of base pairing with the nucleotide residues of the second portion. More preferably, all of the nucleotide residues of the first portion are capable of base pairing with the nucleotide residues of the second portion.

[0039] As used herein, the term "homologous" refers to nucleotide sequence similarity between two regions of the same nucleic acid strand or between regions of two different nucleic acid strands. If a nucleotide residue position of both regions is occupied by the same nucleotide residue, then the regions are homologous at that position. A first region is homologous to a second region if at least one nucleotide residue position of each of the first and second regions is occupied by the same residue. Homology between two regions is expressed in terms of the percentage of nucleotide residue positions of the two regions that are occupied by the same nucleotide residue. As an example, a region having the nucleotide sequence 5'-ATTGCC-3' and a region having the nucleotide sequence 5'-TATGGC-3' have 50% homology. Preferably, the first region comprises a first portion and the second region comprises a second portion, whereby at least about 50%, preferably at least about 75%, at least about 90%, or at least about 95% of the nucleotide residue positions of each of the portions are occupied by the same nucleotide residue. More preferably, all nucleotide residue positions of each of the portions are occupied by the same nucleotide residue.

[0040] The term "host cell" is intended to refer to a cell into which a nucleic acid of the invention, e.g., a recombinant expression vector of the invention, is introduced. The terms "host cell" and "recombinant host cell" are used interchangeably herein. It should be understood that such terms refer not only to the particular subject cell, but also to the progeny or potential progeny of such a cell. Such progeny may not actually be identical to the parent cell, since certain modifications may occur in successive generations due to mutations or environmental influences, but are still included within the scope of the term as used herein. In some embodiments, the host cells described herein are mammalian cells (e.g., Chinese Hamster Ovary (CHO) cells, Hela cells, etc.). In some embodiments, the host cells are immortalized.

[0041] As used herein, the term "interaction", when referring to an interaction between two molecules (e.g., an NGF variant and its binding partner), refers to physical contact (e.g., binding) of the molecules with each other. Generally, such an interaction results in an activity of one or both of the molecules (an activity that produces a biological effect). The activity can be a direct activity of one or both of the molecules. Alternatively, one or both molecules in the interaction may prevent their ligand from binding, and thus become inactive with respect to ligand binding activity (e.g., binding to its ligand and eliciting or inhibiting an immune response). Inhibiting such an interaction results in the destruction of the activity of one or more molecules involved in the interaction. Enhancing such an interaction is the extension or increase of the possibility of said physical contact and the extension or increase of the possibility of said activity.

[0042] As used herein, "isolated protein" refers to a protein (e.g., an NGF variant polypeptide) that is substantially free of other proteins, cellular material, isolation medium, and culture medium when isolated from a cell or produced by recombinant DNA technology, or substantially free of other chemical precursors or other chemicals when chemically synthesized. An "isolated" or "purified" protein or biologically active portion thereof is substantially free of cellular material or other contaminating proteins from the cell or tissue source from which the antibody, polypeptide, peptide, or fusion protein is derived, or substantially free of chemical precursors or other chemicals when chemically synthesized. The term "substantially free of cellular material" includes preparations in which the compositions of the invention are separated from cellular components of isolated or recombinantly produced cells. In one embodiment, the term "substantially free of cellular material" includes preparations having less than about 30%, 20%, 10%, or 5% (by dry weight) cellular material. When an antibody, polypeptide, peptide, or fusion protein, or fragment thereof, e.g., a biologically active fragment thereof, is recombinantly produced, it is also preferably substantially free of culture medium, i.e., culture medium accounts for less than about 20%, more preferably less than about 10%, and most preferably less than about 5% of the protein preparation.

[0043] In some embodiments, a therapeutic composition comprising an NGF variant polypeptide as described herein is used to treat a disease or injury in a subject, including, for example, any disease associated with a deficiency in the amount, level and / or activity of endogenous NGF gene, mRNA and / or protein, such as a neurological disorder (e.g., neurodegeneration). In some embodiments, a therapeutic composition as described herein further comprises another agent capable of treating a disease or injury as described herein.

[0044] In some embodiments, the subject described herein has a neurological disorder (such as neurodegeneration). The NGF variants described herein are believed to be useful in the development, maintenance, or regeneration of neurons, such as central (brain and spinal cord), peripheral (sympathetic, parasympathetic, sensory, and enteric neurons), and motor neurons, in vitro and in vivo. Thus, the NGF variants described herein are useful in methods of treating various neurological diseases and disorders. In a preferred embodiment, the formulations of the present invention are administered to a patient to treat one or more neurological disorders or conditions. As used herein, "neurological disorder" refers to a disorder of the central and / or peripheral nervous system associated with degeneration or injury of neurons. Specific examples of neurological disorders include, but are not limited to, Alzheimer's disease, Parkinson's disease, Huntington's chorea, stroke, ALS, peripheral neuropathy, and other conditions characterized by necrosis or loss of neurons (whether central, peripheral, or motor neurons), in addition to treating nerves damaged due to trauma, burns, renal dysfunction, injury, and the toxic effects of chemotherapeutic agents used to treat cancer and AIDS. For example, peripheral neuropathy associated with several conditions, such as diabetes, AIDS, or chemotherapy-related neuropathy, can be treated using the formulations of the present invention. The compounds and compositions may also be useful in culture media for culturing neural cells in vitro or ex vivo.

[0045] In various embodiments of the invention, NGF variants may be administered to patients with nervous systems damaged by trauma, surgery, stroke, ischemia, infection, metabolic disease, nutritional deficiency, malignancy, or toxic substances, or any condition treatable with NGF, NT-3, BDNF, or NT4-5, to promote neuronal survival or growth. Without limitation, the treatment or effect may vary depending on the particular trk binding function(s) present in the NGF variant. For example, the NGF variants described herein may be used to promote the survival or growth of motor neurons damaged by trauma or surgery. The NGF variants described herein may also be used to treat a variety of conditions, including motor neuron disorders, such as amyotrophic lateral sclerosis (Lou Gehrig's disease), Bell's palsy, and spinal muscular atrophy or paralysis. The NGF variants described herein may be used to treat human neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, epilepsy, multiple sclerosis, Huntington's chorea, Down's syndrome, nerve deafness, and Meniere's disease.

[0046] The NGF variants described herein can be used as cognitive enhancers to enhance learning, for example, in patients with dementia or trauma. Alzheimer's disease, identified by the National Institutes of Aging as the cause of more than 50% of dementia in the elderly, is also the fourth or fifth leading cause of death in the United States for people over 65 years of age. Four million Americans, 40% of Americans over 85 years of age (the fastest growing part of the US population), have Alzheimer's disease. 25% of all patients with Parkinson's disease also suffer from Alzheimer's disease-like dementia. In approximately 15% of patients with dementia, Alzheimer's disease and multi-infarct dementia coexist. The third most common cause of dementia is cognitive impairment due to organic brain disease directly related to alcoholism, which occurs in approximately 10% of alcoholics after Alzheimer's disease and vascular dementia. However, the most consistent abnormality in cognitive impairment due to organic brain disease associated with Alzheimer's disease, as well as alcoholism and vascular dementia, is the degeneration of the cholinergic system occurring from the basal forebrain (BF) to both the codex and hippocampus (Bigl et al. Brain Cholinergic Systems, M. Steriade and D. Biesold, eds., Oxford University Press, Oxford, pp.364-386 (1990)). And there are several other neurotransmitter systems affected by Alzheimer's disease (Davies Med. Res. Rev.3:221 (1983)). However, cognitive impairment, such as that associated with degeneration of the cholinergic neurotransmitter system, is not limited to individuals with dementia. It is also seen in healthy elderly people and rats. A study comparing the degree of learning impairment and the degree of reduction in cortical cerebral blood flow in aged rats shows a good correlation (Berman et al. Neurobiol. Aging 9:691 (1988)).In chronic alcoholism, the resulting organic brain disease, similar to Alzheimer's disease and normal aging, is also characterized by a diffuse reduction in cortical cerebral blood flow in the brain regions where cholinergic neurons originate (basal forebrain) and the brain regions to which they project (cerebral cortex) (Lofti et al., Cerebrovasc. and Brain Metab. Rev 1:2 (1989)). Such dementias may be treated by administration of the NGF variants described herein.

[0047] Additionally, the NGF variants described herein can be used to treat neuropathy, particularly peripheral neuropathy. "Peripheral neuropathy" refers to disorders affecting the peripheral nervous system, often manifesting as one or a combination of motor, sensory, sensorimotor, or autonomic dysfunction. The wide variety of forms exhibited by peripheral neuropathy can each be uniquely attributed to an equally wide number of causes. For example, peripheral neuropathy can be genetically acquired, caused by systemic disease, or induced by toxic substances. Examples include, but are not limited to, diabetic peripheral neuropathy, distal sensorimotor neuropathy, or autonomic neuropathy, such as gastrointestinal hypomotility or bladder tone. Examples of neuropathy associated with systemic disease include post-polio syndrome or AIDS-related neuropathy. Examples of inherited neuropathy include Charcot-Marie-Tooth disease, Refsum disease, abetalipoproteinemia, Tangier disease, Krabbe disease, metachromatic leukodystrophy, Fabry disease, and Dejerine-Sottas syndrome. And, examples of neuropathies caused by toxic substances include those caused by treatment with chemotherapeutic agents such as vincristine, cisplatin, methotrexate, or 3'-azido-3'-deoxythymidine.

[0048] Thus, there is provided a method for treating neural disorder in a mammal, comprising administering to the mammal the NGF variant described herein.Preferably, the neuropathy is peripheral neuropathy, more preferably diabetic peripheral neuropathy, chemotherapy-induced peripheral neuropathy, or HIV-associated neuropathy.Preferably, the peripheral neuropathy affects motor neurons.

[0049] As used herein, the term "nerve growth factor" or "NGF" refers to a group of neurotrophic factors and neuropeptides primarily involved in the growth, maintenance, proliferation and survival of certain target neurons, particularly those that transmit pain, temperature and touch (sensory neurons). The term "NGF" as described herein includes wild-type NGF from any species described herein, as well as any mutant, substituted and / or modified beta chain (NGFβ), such as those exemplified in Table 1, unless otherwise specified. It is perhaps the prototypic growth factor in that it was one of the first to be described. Since it was first isolated in 1956 by Nobel laureates Rita Levi-Montalcini and Stanley Cohen, several biological processes involving NGF have been identified, two of which are the survival of pancreatic beta cells and the regulation of the immune system. When expressed, NGF occurs initially in a 7S, 130-kDa complex of three proteins, namely α-NGF, β-NGF and γ-NGF (ratio 2:1:2). This form of NGF is also called proNGF (NGF precursor). The gamma subunit of this complex acts as a serine protease and cleaves the N-terminus of the beta subunit, thereby activating the protein to functional NGF. The human NGF beta subunit contains 241 amino acids of approximately 26959 Da (Gene Bank ID: NP_002497.2), encoded by the nucleic acid sequence shown in Gene Bank ID: NM_002506.2. Its domain structure is also known in UniProt ID no. P01138. Specifically, for the human NGF sequence shown in SEQ ID NO:5, amino acid residues 1 to 18 are a signal peptide, followed by a propeptide region from positions 19 to 121, and the NGF mature polypeptide ranges from positions 122 to 241 (SEQ ID NO:6). Known amino acid modifications include N-linked glycosylation sites at positions 69 and 114 of SEQ ID NO:5, and disulfide bonds between positions 136 and 201, between positions 179 and 229, and between positions 189 and 231.NGFβ homologues in other organisms are also known in the art, such as chimpanzee NGFβ (NM_001012437.1 and NP_001012439.1), rhesus monkey NGFβ (XM_015148902.1 and XP_015004388.1, and XM_015148898.1 and XP_015004384.1), dog NGFβ (NM_001194950.1 and NP_001181879.1), bovine NGFβ (NM_001099362.1 and NP_001092832.1), mouse NGFβ (NM_001012437.1 and NP_001012439.1), and the like. These include mouse NGF beta (NM_001112698.2 and NP_001106168.1, and NM_013609.3 and NP_038637.1), rat NGF beta (NM_001277055.1 and NP_001263984.1), chicken NGF beta (NM_001293108.1 and NP_001280037.1, and NM_001293109.1 and NP_001280038.1), and Xenopus tropicalis NGF beta (NM_001129924.1 and NP_001123396.1). Mouse NGFβ (NM_013609.3) represents the longer transcript variant 1, which encodes the longer isoform A (NP_038637.1), while NM_001112698.2 refers to variant 2, which contains a different 5' UTR compared to variant 1 and has a deletion in the in-frame portion of the 5' coding region. The resulting isoform B (NP_001106168.1) has a shorter N-terminus compared to isoform A. NGF binds at least tropomyosin receptor kinase A (TrkA) and the low affinity NGF receptor (LNGFR / p75NTR). The NGF portion described herein may include any fragment of full-length NGF. In some embodiments, the NGF portion includes at least the domain for NGF interaction with TrkA or LNGFR. For example, the NGF portion may include amino acid residues 122 to 241 of SEQ ID NO:5. The NGF moieties described herein may include NGF sequences that include substitutions, mutations, modifications, and / or deletions. Some exemplary NGF sequences are listed in Table 1. NGF sequences such as those described in U.S. Patent Nos. 6,333,310 and 7,452,863 are also included within the scope of the present invention.

[0050] The NGF variant polypeptides described herein include NGF portions including full-length NGF polypeptides (either NGF precursor polypeptides or mature NGF polypeptides) or biologically active fragments thereof. The term "biologically active fragments" refers to a portion of any species of wild-type NGF polypeptide, including any possible substitutions, mutations, deletions, insertions, fusions and / or other modification methods, that maintains at least one of the biological functions of the wild-type NGF polypeptide. The term "biological function" of NGF generally refers to the ability to promote the growth, maintenance and survival of neurons and axons, including promoting myelin sheath repair and other related functions. Specifically, the term "biological function" of NGF can also refer to signaling functions via binding to TrkA and / or p75NTR. Several tests of these general and specific functions are known in the art.

[0051] NGF has several domains that, when modified, can affect the specificity of NGF. The N-terminal amino acids of NGF are the major region of NGF that contribute to trkA binding. A significant loss of biological activity and receptor binding was observed in purified homodimers of human and mouse NGF, which represent uniform truncated forms modified at the amino and carboxy termini. Truncated mature NGF species, including the 109 amino acid (10-118) hNGF, resulting from the deletion of the first 9 residues at the N-terminus and the last 2 residues from the C-terminus of purified recombinant human mature NGF, exhibits significantly greater loss of specificity from the human trkA receptor compared to the (1-118) hNGF. 125I-NGF was 300-fold less efficient in replacing hNGF. It has 50-100-fold less activity in dorsal root ganglion and sympathetic ganglion survival compared to (1-118)hNGF. Modification of the 10 amino acid N-terminal region can result in reduced or eliminated TrkA binding. For example, U.S. Patent No. 6,333,310 describes that deletion of the 7-terminal amino acids of NGF (SSSHPIF) or replacement thereof with the N-terminal amino acids of NT-3 (YAEHKS) results in an NGF variant with reduced or absent trkA binding activity. Additionally, PCT Publication WO 95 / 33829 discloses NGF variants lacking NGF activity. In the present disclosure, the NGF portion of the NGF variant polypeptide can include an NGF polypeptide with intact, increased or reduced ability to bind to Trk A and / or p75NTR. In some embodiments, the NGF polypeptide has at least the same binding affinity to Trk A and / or p75NTR as wild-type NGF. In some embodiments, the NGF polypeptide has a higher binding affinity to Trk A and / or p75NTR compared to wild-type NGF. In some other embodiments, the NGF polypeptide has a lower binding affinity to Trk A and / or p75NTR compared to wild-type NGF. In some embodiments, a trkB recruitment modification may be combined with a trkA reduction modification to obtain a variant that binds to both trkC and trkB but not to trkA.

[0052] The NGF variant polypeptides described herein comprise an additional polypeptide in addition to the NGF portion. In some embodiments, the additional polypeptide increases the in vivo stability (e.g., half-life) of the NGF portion. Such an additional polypeptide can be any polypeptide having such a function. For example, such an additional polypeptide can be an immunoglobulin or a biologically active fragment thereof. In some embodiments, such an additional polypeptide comprises any type of Fc (fragment, crystallizable) region of IgG. In some embodiments, such an additional polypeptide comprises human chorionic gonadotropin (hCG) or a biologically active fragment thereof. In some preferred embodiments, such an additional polypeptide comprises at least the carboxy terminal portion (CTP) of hCG.

[0053] As used herein, the term "human chorionic gonadotropin" or "hCG" refers to a group of hormones produced by the placenta after implantation. The presence of hCG is detected by some pregnancy tests (HCG pregnancy strip test). Some cancerous tumors produce this hormone. Thus, elevated levels measured when the patient is not pregnant can lead to a diagnosis of cancer and, if high enough, to paraneoplastic syndromes. However, it is not known whether this production is a cause of carcinogenesis or an effect of carcinogenesis. The pituitary analog of hCG, known as luteinizing hormone (LH), is produced in the pituitary gland of men and women of all ages. With regard to the endogenous forms of hCG, there are various methods for classifying and measuring total hCG, C-terminal peptide total hCG, intact hCG, free β subunit hCG, β core fragment hCG, hyperglycosylated hCG, nicked hCG, αhCG, and pituitary hCG, etc. Concerning pharmaceutical preparations of hCG from animal or synthetic sources, there are many gonadotropin preparations, some of which are medically justified and others of a spurious nature. As of December 6, 2011, the United States Food and Drug Administration banned the sale of "homeopathic" and over-the-counter hCG diet products, declaring them fraudulent and illegal. Human chorionic gonadotropin is a glycoprotein composed of 237 amino acids with a molecular weight of 25.7 kDa. It is a heterodimer, with an α (alpha) subunit identical to luteinizing hormone (LH), follicle-stimulating hormone (FSH), and thyroid-stimulating hormone (TSH), and a β (beta) subunit unique to hCG. The α (alpha) subunit is 92 amino acids long. The beta subunit of the hCG gonadotropin isoform (beta-hCG) contains 145 amino acids encoded by six highly homologous genes arranged in tandem and inverted pairs on chromosome 19q13.3. The two subunits create a small hydrophobic core surrounded by a high surface area to volume ratio: 2.8 times the size of a sphere. Most of the outer amino acids are hydrophilic. The three-dimensional structure of hCG is taught by Wu et al. (1994) Structure 2:545-558.Some examples of amino acid sequences of the β subunit of hCG are listed in Table 1, SEQ ID NOs: 10-12. See Bahl et al. (1972) Biochem. Biophys. Res. Commun. 48:416-422 for a report of both α and β chain sequences of hCG. Human chorionic gonadotropin interacts with the LHCG receptor in the ovary and promotes the maintenance of the corpus luteum at the onset of pregnancy. This allows the corpus luteum to secrete the hormone progesterone early in pregnancy. Progesterone ensures that the uterus becomes rich in a thick lining of blood vessels and capillaries so that it can support the growing fetus. Detection of hCG can be done by any method, such as using a monoclonal antibody that specifically binds to the β subunit of hCG, which can distinguish hCG from LH and FSH. Such antibodies are well known in the art, such as antibodies from OriGene (Rockville, MD) (e.g., TA313616).

[0054] The carboxy-terminal portion of hCG (CTP) can be fused to therapeutic proteins for extended half-life (Fares et al. (2010) Endocrinology 151:4410-4417). CTP refers to a glycosylated amino acid sequence (28mer, SEQ ID NO: 13) derived from human chorionic gonadotropin (HCG). CTP's high biocompatibility, low immunogenicity, and ability to significantly extend the half-life of therapeutic proteins have been well studied. For example, Furuhashi et al. (1995 Mol Endocrinol. 9:54-63) teach that the hCG beta subunit contains a carboxy-terminal extension (i.e., carboxy-terminal peptide (CTP)) with four serine-linked oligosaccharides, which is important for maintaining a long half-life compared to other glycoprotein hormones. In fact, the full-length signal for O-glycosylation is contained primarily within the CTP sequence and is independent of adjacent regions of the recipient protein. Follicle-stimulating hormones (FSH) fused with CTP, developed by Merck and approved by the European Commission in 2010, of which ELONVA® is representative, are used clinically to help women achieve pregnancy in the treatment of infertility. ELONVA® is designed to allow a single injection to replace a week of daily FSH injections for patients. The hCG polypeptide and / or CTP portion described herein may include any hCG / CTP variant, including substitutions, mutations, modifications, and / or deletions. Some exemplary variants are listed in Table 1 (underlined). CTP variants, such as those described in U.S. Pat. No. 6,225,449, may also be included within the scope of the present invention.

[0055] The NGF variant polypeptides described herein may further comprise a third moiety beyond the two described herein. Such a third moiety may comprise a fusion domain that may improve the function and / or stability of the NGF moiety. Well-known examples of such fusion domains include, but are not limited to, polyhistidine, Glu-Glu, glutathione S-transferase (GST), thioredoxin, protein A, protein G, immunoglobulin heavy chain constant region (Fc), maltose binding protein (MBP), or human serum albumin. The fusion domain may be selected to confer desired properties. For example, some fusion domains are particularly useful for the isolation of fusion proteins by affinity chromatography. For affinity purification purposes, relevant matrices for affinity chromatography are used, such as glutathione-, amylase-, and nickel- or cobalt-conjugated resins. Many such matrices are available in "kit" form, such as the Pharmacia GST purification system, and the QIAexpress, which are useful with (HIS6) fusion partners. TMSystems such as the Qiagen fusion domain are available. As another example, a fusion domain may be selected to facilitate detection of the ALK1 ECD polypeptide. Examples of such detection domains include various fluorescent proteins (e.g., GFP), as well as "epitope tags" (usually short peptide sequences for which specific antibodies are available). Well-known epitope tags for which specific monoclonal antibodies are readily available include FLAG, influenza virus hemagglutinin (HA), and c-myc tags. In some cases, the fusion domain is a protease cleavage site, such as for factor Xa or thrombin, which allows the relevant protease to partially digest the fusion protein, thereby releasing the recombinant protein therefrom. The released protein is then isolated from the fusion domain by subsequent chromatographic separation. In some preferred embodiments, the NGF variant polypeptide is fused to a domain that stabilizes the NGF polypeptide in vivo (a "stabilizer" domain). By "stabilization" we mean something that increases serum half-life, whether this is for reduced destruction, reduced clearance by the kidney, or other pharmacokinetic effects. Fusion with the Fc portion of immunoglobulin is known to confer desirable pharmacokinetic properties to a wide range of proteins. Similarly, fusion with human serum albumin may confer desirable properties. Other types of fusion domains that may be selected include multimerization (e.g., dimerization, trimerization) domains and functional domains. In addition, localization sequences may be added to help localize NGF variants to specific cells, tissues or organs. For example, several sequences are known in the art for localizing proteins to the nervous system or other tissues. Such sequences allow recombinant NGF variants to be specifically delivered to targeted cells, tissues or organs for better function and fewer possible side effects.

[0056] Different portions of the NGF variants described herein may be fused together as fusion proteins, with or without linkers. Such linkers may be either natural or chemical linkers. For example, polyGly and Gly-rich linkers are taught in Priyanka et al. (2013) Protein Sci. 22:153-167.

[0057] An important and well-known feature of the genetic code is its degeneracy, which allows more than one coding nucleotide triplet to be used for most of the proteins used to make them. Thus, several different nucleotide sequences may code for a given amino acid sequence. Such nucleotide sequences are considered to be functionally equivalent, since they result in the production of the same amino acid sequence in all organisms (although some organisms may translate some sequences more efficiently than others). Furthermore, sometimes methylated variants of purines or pyrimidines may be found in a given nucleotide sequence. Such methylation does not affect the coding relationship between the trinucleotide codon and its corresponding amino acid.

[0058] In view of the above, the nucleotide sequence of the DNA or RNA encoding the fusion protein or polypeptide of the present invention (or a portion thereof) can be used to derive a fusion protein or polypeptide amino acid sequence, utilizing the genetic code for translating DNA or RNA into amino acid sequences. Similarly, for a fusion protein or polypeptide amino acid sequence, the corresponding nucleotide sequence that can encode the fusion protein or polypeptide can be deduced from the genetic code (which, due to its degeneracy, can result in multiple nucleic acid sequences for a given amino acid sequence). Thus, the description and / or disclosure herein of a nucleotide sequence encoding a fusion protein or polypeptide should be considered to also include a description and / or disclosure of the amino acid sequence encoded by that nucleotide sequence. Similarly, the description and / or disclosure herein of a fusion protein or polypeptide amino acid sequence should be considered to also include a description and / or disclosure of all possible nucleotide sequences that can encode that amino acid sequence.

[0059] Finally, nucleic acid and amino acid sequence information for the loci and biomarkers of the invention (e.g., the biomarkers listed in Table 2 and in the Examples) is well known in the art and is readily available in publicly available databases, such as the National Center for Biotechnology Information (NCBI). For example, examples of nucleic acid and amino acid sequences derived from publicly available sequence databases are provided below.

[0060] [Table 1] TIFF0007597398000002.tif189130 TIFF0007597398000003.tif208156 TIFF0007597398000004.tif189160 TIFF0007597398000005.tif128129

[0061] Table 1 includes nucleic acid molecules comprising a nucleic acid sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or more identity over its entire length to the nucleic acid sequence of SEQ ID NO: 1, 4, 6 and / or 8 listed in Table 1. Such nucleic acid molecules can encode a polypeptide having an NGF function as described herein.

[0062] Table 1 includes polypeptide molecules comprising an amino acid sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or more identity over its entire length to the amino acid sequence of SEQ ID NOs: 2, 3, 5, 7 and / or 9 listed in Table 1. Such polypeptides preferably have an NGF function as described herein.

[0063] The therapeutic compositions described herein can be administered to a subject by any suitable route, alone or in combination with a therapeutically acceptable carrier. Such administration can be systemic (e.g., IV) or local (e.g., to the nerve or cerebrospinal fluid). A preferred route of administration is parenteral (e.g., intravenous or injection). Without limitation, administration of the NGF variants described herein can be performed in a variety of ways, including routes known for a particular indication, including, but not limited to, subcutaneous, intravenous, intracerebral, intranasal, transdermal, intraperitoneal, intramuscular, intrapulmonary, intravaginal, rectal, intraarterial, intralesionally, intrathecal, intraventricular, or intraocular. The NGF variants can be administered continuously by infusion into a fluid reservoir of the CNS, although bolus injections are acceptable using available technologies such as pumps and implants. In some cases, for example, in the treatment of wounds, the NGF variants can be applied directly as a solution or spray. Sustained release systems can be used. In general, NGF variants should be formulated and administered for site-specific delivery, where the condition permits. Administration can be continuous or periodic. Administration can be achieved by implantable pumps with constant or programmable flow rates or by periodic infusion.

[0064] As used herein, a therapeutic agent that "prevents" a disorder or condition refers to a compound that, in a statistical sample, reduces the occurrence of the disorder or condition in a treated sample compared to an untreated control sample, or delays the onset or reduces the severity of one or more symptoms of the disorder or condition compared to an untreated control sample.

[0065] The term "treating" includes prophylactic and / or therapeutic treatment. The term "prophylactic or therapeutic" treatment is art-recognized and includes administration of one or more of the subject compositions to a host. If it is administered prior to clinical signs of an undesirable condition (e.g., a disease or other undesirable condition of a host animal), the treatment is prophylactic (i.e., it protects the host against the onset of the undesirable condition), whereas if it is administered after the manifestation of an undesirable condition, the treatment is therapeutic (i.e., intended to alleviate, ameliorate, or stabilize an existing undesirable condition or its side effects).

[0066] The term "therapeutic effect" refers to a local or systemic effect in animals, particularly mammals, and more particularly humans, caused by a pharmacologically active substance. Thus, the term refers to any substance intended for use in the diagnosis, cure, mitigation, treatment or prevention of disease, or in enhancing desirable physical or mental development and conditions in animals or humans. The phrase "therapeutically effective amount" refers to an amount of a substance that produces some desirable local or systemic effect at a reasonable benefit / risk ratio applicable to any treatment. In some embodiments, the therapeutically effective amount of a compound depends on its therapeutic index, solubility, and the like. For example, a particular compound discovered by the methods of the present invention may be administered in an amount sufficient to produce a reasonable benefit / risk ratio applicable to such treatment.

[0067] In some embodiments, vectors and / or host cells are further provided. One aspect of the invention relates to the use of vectors, preferably expression vectors, comprising a nucleic acid encoding a biomarker listed in Table 2 or a portion or ortholog thereof. As used herein, the term "vector" refers to a nucleic acid molecule capable of transporting another nucleic acid to which it is linked. One type of vector is a "plasmid", which refers to a circular double-stranded DNA loop into which additional DNA segments can be ligated. Another type of vector is a viral vector, in which additional DNA segments can be ligated into the viral genome. Certain vectors can replicate autonomously in a host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication, and episomal mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors) are integrated into the genome of the host cell when introduced into the host cell, and are thereby replicated along with the host genome. Additionally, some vectors can direct the expression of genes to which they are operably linked. Such vectors are referred to herein as "expression vectors". In general, expression vectors for use in recombinant DNA technology are often in the form of plasmids. As used herein, "plasmid" and "vector" may be used interchangeably, as the plasmid is the most commonly used form of vector. However, the invention is intended to include other forms of expression vectors that serve equivalent functions, such as viral vectors (e.g., replication defective retroviruses, adenoviruses and adeno-associated viruses). In one embodiment, an adenoviral vector is used that contains the biomarker nucleic acid molecule.

[0068] The recombinant expression vector of the present invention comprises the nucleic acid of the present invention in a form suitable for expression of the nucleic acid in a host cell, meaning that the recombinant expression vector comprises one or more regulatory sequences (operably linked to the nucleic acid sequence to be expressed) selected based on the host cell to be used for expression. Within a recombinant expression vector, "operably linked" is intended to mean that the nucleotide sequence of interest is linked to a regulatory sequence(s) that allows expression of the nucleotide sequence (e.g., in an in vitro transcription / translation system or in a host cell when the vector is introduced into the host cell). The term "regulatory sequence" is intended to include promoters, enhancers, and other expression control elements (e.g., polyadenylation signals). Such regulatory sequences are described, for example, in Goeddel; Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, CA (1990). Regulatory sequences include those that direct constitutive expression of a nucleotide sequence in many types of host cells and those that direct expression of a nucleotide sequence only in certain host cells (e.g., tissue-specific regulatory sequences). Those skilled in the art will appreciate that the design of the expression vector can depend on factors such as the choice of the host cell to be transformed, the level of expression of protein desired, etc. The expression vectors of the invention can be introduced into host cells to produce proteins or peptides (including fusion proteins or peptides) encoded by the nucleic acids described herein.

[0069] The recombinant expression vector of the present invention can be designed for expression of a desired polypeptide in prokaryotic or eukaryotic cells. For example, NGF variant polypeptides can be expressed in bacterial cells, such as E. coli, insect cells (using baculovirus expression vectors), yeast cells, or mammalian cells. Suitable host cells are further discussed in Goeddel, Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, CA (1990). Alternatively, the recombinant expression vector can be transcribed and translated in vitro, for example, using T7 promoter regulatory sequences and T7 polymerase. Examples of suitable inducible non-fusion E. coli expression vectors include pTrc (Amann et al., (1988) Gene 69:301-315) and pET 11d (Studier et al., Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, California (1990) 60-89). Examples of suitable yeast expression vectors include pYepSec1 (Baldari, et al., (1987) EMBO J. 6:229-234), pMFa (Kurjan and Herskowitz, (1982) Cell 30:933-943), pJRY88 (Schultz et al., (1987) Gene 54:113-123), and pYES2 (Invitrogen Corporation, San Diego, Calif.). Examples of suitable baculovirus expression vectors useful for insect cell hosts include the pAc series (Smith et al. (1983) Mol. Cell Biol. 3:2156-2165) and the pVL series (Lucklow and Summers (1989) Virology 170:31-39).Examples of suitable mammalian expression vectors include pCDM8 (Seed, B. (1987) Nature 329:840) and pMT2PC (Kaufman et al. (1987) EMBO J. 6:187-195).

[0070] In another embodiment, the recombinant mammalian expression vector can selectively direct expression of the nucleic acid in a particular cell type (e.g., tissue-specific regulatory elements are used to express the nucleic acid). Tissue-specific regulatory elements are known in the art. Non-limiting examples of suitable tissue-specific promoters and / or regulatory sequences for promoting gene expression in the vertebrate nervous system and neural tissues are well known in the art (see, e.g., Timmusk et al. (1993) Neuron 10(3):475-489; Kaneko and Sueoka (1993) Proc Natl Acad Sci US A. 90(10): 4698-4702; Twyman and Jones (1995) J. Neurogenetics 10:67-101).

[0071] The present invention further provides recombinant expression vectors comprising a nucleic acid molecule of the invention cloned in an antisense orientation into the expression vector. That is, the DNA molecule is operably linked to a regulatory sequence to allow expression (by transcription of the DNA molecule) of an RNA molecule that is antisense to a biomarker mRNA as described herein. Regulatory sequences operably linked to the cloned nucleic acid in antisense orientation can be selected, such as viral promoters and / or enhancers, that direct continuous expression of the antisense RNA molecule in various cell types, or regulatory sequences that direct constitutive, tissue-specific or cell-type specific expression of the antisense RNA. Antisense expression vectors can be in the form of recombinant plasmids, phagemids or attenuated viruses, in which antisense nucleic acids are produced under the control of high efficiency regulatory regions, with activity that can be determined by the cell type into which the vector is introduced.

[0072] Another aspect of the present invention relates to a host cell into which a recombinant expression vector of the present invention is introduced. The terms "host cell" and "recombinant host cell" are used interchangeably herein. It should be understood that such terms refer not only to the particular subject cell, but also to the progeny or potential progeny of such a cell. Because certain modifications may occur in successive generations due to mutation or environmental influences, such progeny may not actually be identical to the parent cell, but are still within the scope of the term as used herein.

[0073] Host cells can be either prokaryotic or eukaryotic. For example, biomarker proteins can be expressed in bacterial cells (such as E. coli), insect cells, yeast or mammalian cells (such as Fao hepatoma cells, primary hepatocytes, Chinese hamster ovary cells (CHO) or COS cells). Other suitable host cells are known to those skilled in the art.

[0074] Vector DNA can be introduced into prokaryotic or eukaryotic cells by conventional transformation or transfection techniques. As used herein, the terms "transformation" and "transfection" are intended to refer to various art-recognized techniques for introducing foreign nucleic acid (e.g., DNA) into host cells, such as calcium phosphate or calcium chloride co-precipitation, DEAE-dextran mediated transfection, lipofection, or electroporation. Suitable methods for transforming or transfecting host cells can be found in Sambrook, et al. (Molecular Cloning: A Laboratory Manual. 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989) and other laboratory manuals.

[0075] A cell culture comprises host cells, medium and other by-products. Suitable media for cell culture are well known in the art. The biomarker polypeptide or fragments thereof may be secreted and isolated from a mixture of cells and medium containing the polypeptide. Alternatively, the biomarker polypeptide or fragments thereof may be retained in the cytoplasm, and the cells are harvested, lysed, and the protein or protein complex isolated. The biomarker polypeptide or fragments thereof may be isolated from the cell culture medium, the host cells, or both, using techniques known in the art for purifying proteins, such as ion exchange chromatography, gel filtration chromatography, ultrafiltration, electrophoresis, and immunoaffinity purification using antibodies specific for particular epitopes of the biomarker or fragments thereof. In other embodiments, heterologous tags may be used for purification purposes (e.g., epitope tags, FC fusion tags, etc.), according to standard methods known in the art.

[0076] Thus, nucleotide sequences encoding all or selected portions of a biomarker polypeptide may be used to produce recombinant forms of the protein through microbial or eukaryotic cell processes. Polynucleotide constructs, such as ligation of sequences into expression vectors, and transformation or transfection into either eukaryotic (yeast, avian, insect or mammalian) or prokaryotic (bacterial cell) hosts are standard procedures. Similar procedures, or variations thereof, may be used to prepare recombinant biomarker polypeptides or fragments thereof by microbial means or tissue culture techniques in accordance with the invention.

[0077] The host cells of the invention, e.g., prokaryotic or eukaryotic host cells in culture, can be used to produce (i.e., express) a biomarker protein. Thus, the invention further provides methods of producing a biomarker protein using the host cells of the invention. In one embodiment, the method comprises culturing a host cell of the invention (in which a recombinant expression vector encoding a biomarker has been introduced) in a suitable medium until the biomarker protein is expressed. In another embodiment, the method further comprises isolating the biomarker protein from the medium or the host cell.

[0078] II. Subject

[0079] In some embodiments, a subject suitable for the compositions and methods disclosed herein is a mammal (e.g., mouse, rat, primate, non-human mammal, domestic animal, such as dog, cat, cow, horse, etc.), preferably a human. In other embodiments, the subject is an animal model of a metabolic disturbance or intolerance.

[0080] In other embodiments of the methods of the invention, the subject has not undergone treatment for the disease or disorder, hi yet other embodiments, the subject has undergone treatment for the disease or disorder.

[0081] The methods of the invention can be used to determine and / or treat responsiveness in subjects, such as those described herein, to the compositions described herein, alone or in combination with other treatments to achieve weight loss.

[0082] III. Pharmaceutical Compositions The present invention provides pharma- ceutical acceptable compositions of the compositions disclosed herein.As described in detail below, the pharmaceutical compositions of the present invention can be specially formulated for administration in solid or liquid form, for example, suitable for formulation for: (1) oral administration, such as drenches (aqueous or non-aqueous solutions or suspensions), tablets, boluses, powders, granules, pastes; (2) parenteral administration, such as subcutaneous, intramuscular or intravenous injection, for example as sterile solutions or suspensions; (3) topical application, such as creams, ointments, eye drops, or sprays applied to the skin or eyes; (4) vaginally or rectally, such as pessaries, creams or foams; or (5) aerosols, such as aqueous aerosols, liposomal preparations or solid particles.

[0083] The phrase "pharmacologically acceptable" is used herein to refer to agents, materials, compositions and / or dosage forms that are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit / risk ratio.

[0084] As used herein, the phrase "pharmacologically acceptable carrier" refers to a pharma- ceutically acceptable material, composition, or vehicle, such as a liquid or solid filler, diluent, excipient, solvent, or encapsulating material, that is involved in carrying or transporting a chemical of interest from one organ or part of the body to another organ or part of the body. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not deleterious to the subject. Some examples of materials that can serve as pharma- ceutically acceptable carriers include: (1) sugars, such as lactose, glucose, and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose and its derivatives, such as sodium carboxymethylcellulose, ethylcellulose, and cellulose acetate; (4) tragacanth powder; (5) malt; (6) gelatin; (7) talc; (8) excipients, such as cocoa butter and suppository wax; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, and the like. (10) glycols such as propylene glycol; (11) polyols, e.g., glycerin, sorbitol, mannitol, and polyethylene glycol; (12) esters such as ethyl oleate and ethyl laurate; (13) agar; (14) buffers such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18) Ringer's solution; (19) ethyl alcohol; (20) phosphate buffers; and (21) other non-toxic compatible substances used in pharmaceutical formulations.

[0085] The pharmaceutical compositions (preparations) may be administered to a subject by any of a number of routes of administration, including, for example, orally (e.g., as drenches such as aqueous or non-aqueous solutions or suspensions, tablets, capsules (including sprinkle capsules and gelatin capsules), boluses, powders, granules, pastes for application to the tongue); absorption through the oral mucosa (e.g., sublingually); anally, rectally, or vaginally (e.g., as a pessary, cream, or foam); parenterally (e.g., intramuscularly, intravenously, subcutaneously, or intrathecally, e.g., as a sterile solution or suspension); intranasally; intraperitoneally; subcutaneously; transdermally (e.g., as a patch applied to the skin); and topically (e.g., as a cream, ointment, or spray applied to the skin, or as eye drops). The compound may be formulated for inhalation. In certain embodiments, the compound may simply be dissolved or suspended in sterile water. Details of suitable routes of administration and compositions suitable therefor can be found, for example, in U.S. Pat. Nos. 6,110,973, 5,763,493, 5,731,000, 5,541,231, 5,427,798, 5,358,970 and 4,172,896, and patents cited therein.

[0086] The formulations may conveniently be provided in unit dosage form and may be prepared by any method well known in the art of pharmacy. The amount of active ingredient that can be combined with carrier materials to produce a single dosage form will vary depending on the host being treated, the particular mode of administration. The amount of active ingredient that can be combined with carrier materials to produce a single dosage form will generally be the amount of compound that produces a therapeutic effect. Generally, out of 100 percent, this amount will range from about 1 percent to about 99 percent of the active ingredient, preferably from about 5 percent to about 70 percent, and most preferably from about 10 percent to about 30 percent.

[0087] Methods of preparing these formulations or compositions include the step of bringing into association an active compound, such as a compound of the present invention, with the carrier and, optionally, one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association a compound of the present invention with liquid carriers, or finely divided solid carriers, or both, and then, if necessary, shaping the product.

[0088] Alternatively, or in addition, the compositions may be formulated for delivery via a catheter, stent, wire, or other intraluminal device, which may be particularly useful for delivery to the bladder, urethra, ureter, rectum, or intestine.

[0089] Ophthalmic formulations, eye ointments, solutions, etc. are also considered to be within the scope of the present invention. Exemplary ophthalmic formulations are described in U.S. Patent Application Publication Nos. 2005 / 0080056, 2005 / 0059744, 2005 / 0031697 and 2005 / 004074 and U.S. Patent No. 6,583,124, the contents of which are incorporated herein by reference. If necessary, the liquid ophthalmic formulation has similar properties to tears, aqueous humor or vitreous humor, or is compatible with such fluids. The preferred intraocular administration route is topical administration (e.g., topical administration such as eye drops, or administration via implant).

[0090] The phrases "parenteral administration" and "parenterally administered" as used herein refer to modes of administration other than enteral and topical administration, usually by injection, including, but not limited to, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal and intrasternal injection and infusion. Pharmaceutical compositions suitable for parenteral administration include one or more active compounds in combination with one or more pharma- ceutically acceptable sterile isotonic aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, or sterile powders that can be reconstituted into a sterile injectable solution or dispersion immediately prior to use, which may include antioxidants, buffers, bacteriostats, solutes that render the formulation isotonic with the blood of the intended recipient, or suspending or thickening agents.

[0091] Examples of suitable aqueous and non-aqueous carriers that can be used in the pharmaceutical compositions of the present invention include water, ethanol, polyols (e.g., glycerol, propylene glycol, polyethylene glycol, etc.) and suitable mixtures thereof, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of coating materials such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.

[0092] Injectable depot forms are made by forming microencapsulated matrices of the subject drugs in biodegradable polymers such as polylactide-polyglycolide. Depending on the ratio of drug to polymer and the nature of the particular polymer used, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions that are compatible with body tissues.

[0093] For use in the methods of the invention, the active compound may be provided per se or as a pharmaceutical composition comprising, for example, 0.1 to 99.5% (more preferably 0.5 to 90%) of the active ingredient in combination with a pharma- ceutically acceptable carrier.

[0094] The administration method may also include rechargeable or biodegradable devices.For the controlled delivery of drugs, including proteinaceous biopharmaceuticals, various sustained release polymeric devices have been developed and tested in vivo in recent years.Various biocompatible polymers, including both biodegradable and non-degradable polymers (including hydrogels), may be used to form implants for sustained release of compounds at specific target sites.

[0095] Actual dosage levels of the active ingredients in pharmaceutical compositions may be varied to obtain an amount of active ingredient that is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient.

[0096] In some embodiments, the NGF variants of the present invention may be used alone or may be administered in conjunction with another type of therapeutic agent.

[0097] Examples of pharma- ceutically acceptable antioxidants include: (1) water-soluble antioxidants, such as ascorbic acid, cysteine ​​hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite, and the like; (2) oil-soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, α-tocopherol, and the like; and (3) metal chelating agents, such as citric acid, ethylenediaminetetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, and the like.

[0098] In some embodiments, the present invention also provides gene therapy for the in vivo production of the NGF variants described herein. Such therapy can achieve its therapeutic effect by introducing nucleic acid encoding the NGF variants described herein into cells or tissues with the disorders listed above. Delivery of the nucleic acid described herein can be achieved using recombinant expression vectors, such as chimeric viruses or colloidal dispersion systems. Targeted liposomes can also be used for therapeutic delivery of the NGF variants described herein.

[0099] Various viral vectors that can be used in the gene therapy taught herein include adenovirus, herpes virus, vaccinia, or preferably RNA viruses such as retroviruses. Preferably, the retroviral vector is a derivative of a murine or avian retrovirus. Examples of retroviral vectors that can insert a single foreign gene include, but are not limited to, Moloney murine leukemia virus (MoMuLV), Harvey murine sarcoma virus (HaMuSV), mouse mammary tumor virus (MuMTV), and Rous sarcoma virus (RSV). Some additional retroviral vectors can incorporate multiple genes. All of these vectors can transfer or incorporate genes for selectable markers so that transduced cells can be identified and generated. Retroviral vectors can be made target specific, for example, by adding sugars, glycolipids, or proteins. Preferred targeting is achieved by using antibodies. Those skilled in the art will appreciate that specific polynucleotide sequences can be inserted into the retroviral genome or attached to the viral envelope to allow for target specific delivery of retroviral vectors containing the NGF variants described herein. In a preferred embodiment, the vector is targeted to the nervous system, or any cell, tissue or organ that has a deficiency in wild-type NGF levels and / or a defective NGF mutant.

[0100] Alternatively, cultured cells can be directly transfected with plasmids encoding the retroviral structural genes gag, pol, and env by conventional calcium phosphate transfection. These cells can then be transfected with a vector plasmid containing the gene of interest. The resulting cells release the retroviral vector into the culture medium. EXAMPLES

[0101] Example 1: Preparation of long-lasting recombinant human nerve growth factor (rhNGF) Cloning of NGF-CTP NGF (238 amino acids) is initially a complex of α-NGF, β-NGF and γ-NGF, and the γ subunit cleaves the N-terminus of the β subunit, activating the protein to functional NGF (120 amino acids). The full-length NGF gene (714-bp) was amplified using a plasmid carrying the full-length human NGF gene, with 5'-ATCTC GAGCA CCATG TCCAT GTTGT TCTAC ACTCT GA- 3' (SEQ ID NO: 14) as the forward primer (U1) and 5'-TGGAG CCTTG GAAGA GCTAG AGGCT CTTCT CACAG CCTT-3' (SEQ ID NO: 15) as the reverse primer (R1). The CTP gene from human HCG was synthesized by Sangon Biotech (Shanghai) Co., Ltd., and the forward (U2) and reverse (R2) primers designed to amplify this gene were 5'-AAGGC TGTGA GAA GA GCCTC TAGCT CTTCC AAGGC TCCA-3' (SEQ ID NO: 16) and 5'-TTTGC GGCCG CTTACT ACTGG GGCAG AATA -3' (SEQ ID NO: 17), respectively. Thus, the NGF sequence and the CTP sequence were amplified and analyzed by gel electrophoresis, followed by gel extraction to obtain the PCR products. PCR products of NGF (1 μL) and HCG CTP (1 μL) were used as templates, and PCR overlap extension was performed using U1 and R2 as forward and reverse primers, respectively. The PCR amplification consisted of 30 cycles of an initial step (94°C, 3 min), a denaturation step (94°C, 30 s), an annealing step (58°C, 30 s) and an extension step (72°C, 1 min), followed by a final extension step (72°C, 7 min). The PCR products were analyzed by gel electrophoresis and then gel extracted. The genes from the gel extraction were ligated into pMC-18T vector, and the positive clones were then screened and selected for further gene sequencing. Clones with the correct sequence were kept for further construction. The gene sequence is shown in SEQ ID NO:1 and the amino acid sequence is shown in SEQ ID NO:2 (Table 1).

[0102] Construction of NGF-CTP expression factor The NGF-CTP fragment was derived by digestion of pMC-18T / NGF-CTP plasmid with XhoI and NotI (New England Biolabs Ltd.) as restriction enzymes. The fragment was then ligated into pCI-neo vector pretreated with XhoI and NotI. After overnight ligation reaction at 16°C, the product was transformed into DH5α competent cells and screened on LB agar plates containing ampicillin. Positive clones were first verified by PCR and further evaluated by gene sequencing. The structure of the PCI-neo / NGF-CTP plasmid is shown in Figure 1.

[0103] Construction of a mammalian cell expression system for rhNGF-CTP The PCI-neo / NGF-CTP plasmid was introduced into CHO-S cells (Invitrogen Co.) by electroporation using a Gene Pulser XcellTM electroporation system (Bio-Rad Laboratories, Inc.) at 160 V for 150 ms. The electroporated cells were transferred to and cultured in 35 mm tissue culture dishes containing DMEM-F12 culture medium supplemented with 10% fetal bovine serum (FBS). After 2 days, G418 (Sigma-Aldrich Co. LLC.) was added to a final concentration of 600 μg mL -1 The remaining monoclonal cells after G418 treatment were transferred to 96-well plates for further analysis of protein expression levels by dot blotting. Cells with high expression levels were selected for subsequent suspension culture.

[0104] After suspension culture, the cells with the highest expression level were transferred to tissue culture flasks (40 mL, Corning Inc.) for further selection of productive cells under serum-free conditions. The cells were cultured at 37°C in CD CHO medium (Invitrogen Co.), cell growth was evaluated, and the expression level of the recombinant protein was assayed by ELISA (R&D Systems, Inc.). Further subclones were used to confirm that the recombinant 1B2 cells were the prototype cell line for rhNGF-CTP production. Before developing a master cell bank and a working cell bank for rhNGF-CTP expression, the cell line was extensively tested for sterility and contaminants (e.g., bacteria and mycoplasma).

[0105] Purification of rhNGF-CTP The working cell bank was restored to produce rhNGF-CTP in a WAVE bioreactor (10 L, GE Healthcare) using serum-free culture medium. Cells were grown in the bioreactor for 12 days in a fed-batch format before harvesting. Supernatants were collected, concentrated with a centrifugal filter, and purified using protein chromatography on an AKTA purifier (GE Healthcare). Samples were first applied to Sepharose Fastflow (GE Healthcare) and diluted with sodium chloride (1 mol L -1 The recombinant protein was eluted with a buffer containing 1,2-dichlorophenyl ether (DPPA) and 1,2-dichlorophenyl ether (DPPA). Phenyl Fastflow (GE Healthcare) and Superdex 75 (GE Healthcare) were then used for further purification. The purity of the recombinant protein was more than 95% as shown by SDS-PAGE gel electrophoresis (Figure 2).

[0106] Characterization of rhNGF-CTP and its biological activity N-terminal sequencing of purified rhNGF-CTP aligned well with the gene sequence of human NGF with the first five amino acids (SSSHP) being identical, indicating a correct truncation of α-NGF. The sequence of rhNGF-CTP (148 amino acids) is shown in SEQ ID NO:3. The calculated molecular weight of non-glycosylated rhNGF-CTP was 16273 Da, and the molecular weight of purified rhNGF-CTP determined by mass spectrometry was 18605 Da. The difference in molecular weight is due to glycosylation at CTP.

[0107] The biological activity of rhNGF-CTP was then examined by two cellular assays. First, a TF-1 cell proliferation assay was used to assess the dose-dependent stimulation of NGF-induced TF-1 cell proliferation, which functions via binding to the high affinity TrkA receptor on the TF-1 cell surface. The biological activity of NGF was calculated by the cell proliferation rate (MTT assay) of stimulated TF-1 cells. The rhNGF standard was an NGF sample from the National Institute for Biological Standards and Control (NIBSC) (UK) and was 1 × 106 AU mg -1 The specific activities of rhNGF-CTP and NGF standard in the TF-1 cell proliferation assay were 1.2 × 10 6 AU mg -1 and 1.8 x 10 6 AU mg -1 No significant difference was observed. The second method to semiquantitatively measure NGF activity is sprouting of chick embryo dorsal root ganglia (DRG). Here, mouse NGF from the National Institutes for Food and Drug Control of China was used as the standard sample. The specific activities of rhNGF-CTP and NGF standard were 1.7 × 10 5 AU mg -1 Above 5×10 5 AU mg -1 A slight reduction in biological activity was seen for rhNGF-CTP.

[0108] Pharmacokinetic study of hNGF-CTP in rats Sprague Dawley® rats were subjected to a pharmacokinetic study of rhNGF-CTP. Six rats (body weight 300-400 g) were divided into two groups and treated with either rhNGF or rhNGF-CTP. Rats were anesthetized with napenthal (1%) and administered rhNGF or rhNGF-CTP at 30 μg kg -1 Body weight was administered by intramuscular injection. Blood samples were taken from the tail at 0.5, 1, 2, 4, 6, 8, 12 and 24 hours after injection. Plasma NGF concentrations were determined using ELISA as shown in Figure 3. The half-life of rhNGF was calculated to be 3.9 hours in rats, while the half-life of rhNGF-CTP was extended to 10.0 hours, representing a 2.5-fold increase.

[0109] Incorporation by Reference All publications, patents, and patent applications mentioned in this specification are incorporated by reference in their entirety as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference. In case of conflict, the present application, including definitions herein, will control.

[0110] Also, all polynucleotide and polypeptide sequences that reference accession numbers associated with public database entries, such as those maintained by The Institute for Genomic Research (TIGR) on the World Wide Web at tigr.org and / or the National Center for Biotechnology Information (NCBI) on the World Wide Web at ncbi.nlm.nih.gov, are incorporated by reference in their entirety.

[0111] Equivalent Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the scope of the claims appended hereto. The present invention includes, for example, the following embodiments: [Embodiment 1] The following: (i) a first portion comprising a full-length nerve growth factor (NGF) polypeptide sequence, or a biologically active fragment thereof; and (ii) a second portion comprising an additional polypeptide that increases the half-life of the NGF polypeptide sequence, or a biologically active fragment thereof, in the bloodstream of a human. A polypeptide comprising: [Embodiment 2] The polypeptide described in embodiment 1, wherein the first portion comprises a full-length NGF polypeptide sequence. [Embodiment 3] The polypeptide described in embodiment 1, wherein the first portion comprises a fragment having the biological activity of NGF. [Embodiment 4] A polypeptide described in any one of embodiments 1 to 3, wherein the first portion comprises a human NGF sequence. [Embodiment 5] The polypeptide described in embodiment 4, wherein the human NGF sequence is at least 70% identical to sequence number 5. [Embodiment 6] The polypeptide described in embodiment 5, wherein the human NGF sequence is at least 80% identical to sequence number 5. [Embodiment 7] The polypeptide described in embodiment 6, wherein the human NGF sequence is at least 90% identical to sequence number 5. [Embodiment 8] The polypeptide described in embodiment 7, wherein the human NGF sequence is at least 95% identical to sequence number 5. [Embodiment 9] The polypeptide described in embodiment 8, wherein the human NGF sequence is at least 99% identical to sequence number 5. [Embodiment 10] The polypeptide described in embodiment 9, wherein the human NGF sequence comprises sequence number 5. [Embodiment 11] The polypeptide described in embodiment 3, wherein the first portion is capable of binding to at least one binding partner of NGF, and optionally the at least one binding partner of NGF is tropomyosin receptor kinase A (TrkA) or low affinity NGF receptor (LNGFR / p75NTR). [Embodiment 12] A polypeptide described in embodiment 11, wherein the first portion comprises amino acid residues from positions 122 to 241 of SEQ ID NO:5. [Embodiment 13] A polypeptide described in any one of embodiments 1 to 12, wherein the second portion comprises full-length human chorionic gonadotropin (HCG) or a biologically active fragment thereof. [Embodiment 14] A polypeptide described in any one of embodiments 1 to 13, wherein human chorionic gonadotropin (HCG) comprises an amino acid sequence selected from SEQ ID NOs: 10 to 12. [Embodiment 15] A polypeptide described in any one of embodiments 1 to 14, wherein the second portion comprises the carboxy-terminal portion (CTP) of HCG. [Embodiment 16] A polypeptide described in any one of embodiments 1 to 15, wherein the second portion comprises an amino acid sequence that is at least 70% identical to SEQ ID NO: 13, and optionally the second portion comprises an amino acid sequence that is at least 75%, 80%, 90%, 95, 99% or more identical to SEQ ID NO: 13. [Embodiment 17] A polypeptide described in any one of embodiments 1 to 16, wherein the second portion comprises the amino acid sequence of SEQ ID NO: 13. [Embodiment 18] A polypeptide described in any one of embodiments 1 to 17, wherein the second portion comprises at least one glycosylation site. [Embodiment 19] A polypeptide described in any one of embodiments 1 to 18, wherein the first portion and the second portion are fused to each other with or without a linker. [Embodiment 20] The polypeptide of embodiment 19, wherein the first portion is fused to the N-terminus of the second portion. [Embodiment 21] The polypeptide of embodiment 19, wherein the first portion is fused to the C-terminus of the second portion. [Embodiment 22] A polypeptide described in any of embodiments 1 to 20, comprising an amino acid sequence that is at least 70% identical to SEQ ID NO: 2 or 3, and optionally comprising an amino acid sequence that is at least 75%, 80%, 90%, 95, 99% or 100% identical to SEQ ID NO: 2 or 3. [Embodiment 23] The polypeptide according to any one of embodiments 1 to 22, wherein the polypeptide has an in vivo half-life that is at least 2.5 times the in vivo half-life of the NGF polypeptide sequence alone. [Embodiment 24] The polypeptide according to any one of embodiments 1 to 23, further comprising a label, such as a label for purification and / or a fluorescent tag. [Embodiment 25] A polypeptide described in any of embodiments 1 to 24, further comprising a third portion comprising a fusion domain that increases the function and / or stability of the NGF polypeptide sequence or a biologically active fragment thereof in the human bloodstream. [Embodiment 26] A polynucleotide encoding the polypeptide described in any one of embodiments 1 to 25. [Embodiment 27] A polynucleotide described in embodiment 26, comprising a nucleic acid sequence that is at least 70% identical to sequence number 1. [Embodiment 28] A polynucleotide described in embodiment 26 or 27, comprising a nucleic acid sequence that is at least 80% identical to sequence number 1. [Embodiment 29] A polynucleotide described in any one of embodiments 26 to 28, comprising a nucleic acid sequence that is at least 90% identical to SEQ ID NO:1. [Embodiment 30] A polynucleotide described in any one of embodiments 26 to 29, comprising a nucleic acid sequence that is at least 95% identical to sequence number 1. [Embodiment 31] A polynucleotide described in any one of embodiments 26 to 30, comprising a nucleic acid sequence that is at least 99% identical to SEQ ID NO:1. [Embodiment 32] A polynucleotide described in any one of embodiments 26 to 31, comprising the nucleic acid sequence of SEQ ID NO: 1. [Embodiment 33] A polynucleotide according to any one of embodiments 26 to 32, wherein the polynucleic acid is capable of hybridizing to a nucleic acid sequence complementary to SEQ ID NO:1 under stringent conditions, optionally including overnight hybridization at 65°C in 50% v / v formamide, 5 x SSC, 2% w / v blocking agent, 0.1% N-lauroyl sarcosine, 0.3% SDS, and a wash in 5 x SSC at about 65°C. [Embodiment 34] A polynucleotide described in any one of embodiments 26 to 33, further comprising a label, such as a purification label and / or a fluorescent tag. [Embodiment 35] An expression vector capable of expressing the polypeptide described in any one of embodiments 1 to 25, and / or an expression vector comprising the polynucleotide described in any one of embodiments 26 to 34. [Embodiment 36] The expression vector described in embodiment 35, wherein the expression vector is a plasmid, a cosmid, a viral vector, a recombinant expression vector, or a targeted liposome. [Embodiment 37] The expression vector described in embodiment 36, wherein the expression vector is a viral vector, and the viral vector is an adenovirus vector, a herpes virus vector, a vaccinia virus vector, a chimeric virus, a colloidal dispersion system, or an RNA vector. [Embodiment 38] The expression vector described in embodiment 37, wherein the RNA vector is a retroviral vector. [Embodiment 39] An expression vector described in embodiment 38, wherein the retroviral vector is a mouse retrovirus or a derivative thereof. [Embodiment 40] The expression vector described in embodiment 38, wherein the retroviral vector is an avian retrovirus or a derivative thereof. [Embodiment 41] A host cell comprising the expression vector according to any one of embodiments 35 to 40. [Embodiment 42] The following: (i) culturing the host cell of embodiment 41 in a cell culture medium; and (ii) expressing the polypeptide according to any one of embodiments 1 to 25 The method includes: [Embodiment 43] Further (iii) purifying the polypeptide according to any one of embodiments 1 to 25 from the cell culture medium. 43. The method of embodiment 42, comprising: [Embodiment 44] A composition comprising a polypeptide described in any one of embodiments 1 to 25, a polynucleotide described in any one of embodiments 26 to 34, an expression vector described in any one of embodiments 35 to 40, or a host cell described in embodiment 41. [Embodiment 45] A pharmaceutical composition comprising the composition described in embodiment 44 and a pharma- ceutically acceptable carrier. [Embodiment 46] The pharmaceutical composition described in embodiment 45, wherein the pharma- ceutically acceptable carrier is a colloidal dispersion system or a targeted liposome. [Embodiment 47] The pharmaceutical composition of embodiment 45 or 46, wherein the composition is formulated for administration in solid or liquid form. [Embodiment 48] The pharmaceutical composition of any of embodiments 45 to 47, wherein the composition is formulated for intra-arterial, intracerebral, intralesional, intramuscular, intranasal, intraocular, intraperitoneal, intrapulmonary, intrarectal, intrathecal, intravaginal, intravenous, intraventricular, oral, parenteral, subcutaneous, or topical administration. [Embodiment 49] A pharmaceutical composition described in any of embodiments 45 to 48, wherein the composition is in the form of an aqueous suspension or solution, a non-aqueous suspension or solution, a sterile solution, a tablet, a bolus, a powder, granules, a paste, a cream, an ointment, an eye drop, a topical spray, a pessary, a foam, an aerosol, a liposomal formulation, or a solid particle. [Embodiment 50] A pharmaceutical composition described in any one of embodiments 45 to 49, wherein the composition is administered continuously. [Embodiment 51] A method for treating a disease or injury associated with a deficiency and / or defect in nerve growth factor (NGF), comprising administering to a subject in need thereof a therapeutically effective amount of a polypeptide described in any one of embodiments 1 to 25, a polynucleotide described in any one of embodiments 26 to 34, a composition described in embodiment 44, or a pharmaceutical composition described in any one of embodiments 45 to 50. [Embodiment 52] The method of embodiment 51, further comprising administering to the subject an additional drug and / or therapy for treating the disease or disorder. [Embodiment 53] The method of embodiment 51 or 52, wherein the disease or disorder is a neurological disorder. [Embodiment 54] The method of embodiment 53, wherein the neurological disorder is amyotrophic lateral sclerosis (Lou Gehrig's disease), Alzheimer's disease, Bell's palsy, dementia, Down's syndrome, epilepsy, Huntington's chorea, Meniere's disease, multiple sclerosis, nerve hearing loss, stroke, hypoxic-ischemic encephalopathy, cerebral palsy, paralysis, Parkinson's disease, peripheral neuropathy, optic neuropathy or spinal muscular atrophy. [Embodiment 55] The method of embodiment 54, wherein the neuropathy is a peripheral neuropathy, and the peripheral neuropathy is a polyneuropathy or a mononeuropathy. [Embodiment 56] The method of embodiment 54, wherein the neuropathy is an optic neuropathy, and the optic neuropathy is an anterior or posterior ocular degenerative disease, a chronic allergic inflammatory disorder of the ocular surface, a traumatic optic neuropathy, glaucoma, neurotrophic keratopathy, herpes simplex keratitis, or corneal healing. [Embodiment 57] The method described in any one of embodiments 53 to 56, wherein the neuropathy is caused by necrosis or loss of central neurons, peripheral neurons, motor neurons, or sensory neurons, trauma, renal dysfunction, injury, surgery, ischemia, infection, metabolic disease, nutritional deficiency, malignant tumors, toxic substances, or chemotherapy. [Embodiment 58] The method according to any one of embodiments 51 to 57, wherein the subject is a mammal. [Embodiment 59] A method for promoting neuronal growth and / or proliferation in a subject in need thereof, comprising administering to the subject an effective amount of the polypeptide according to any one of embodiments 1 to 25, the composition according to embodiment 44, or the pharmaceutical composition according to any one of embodiments 45 to 50. [Embodiment 60] The method of embodiment 59, wherein the subject is a mammal.

[0112] [Sequence table] SEQUENCE LISTING <110> VIVIBABA, INC. <120> COMPOSITIONS AND METHODS FOR RECOMBINANT NERVE GROWTH FACTOR <150> US62 / 457,499 <151> 2017-02-10 <160> 20 <170> PatentIn version 3.5 <210> 1 <211> 810 <212> DNA <213> Homo sapiens <400> 1 atgtccatgt tgttctacac tctgatcaca gcttttctga tcggcataca ggcggaacca 60 cactcagaga gcaatgtccc tgcaggacac accatccccc aagcccactg gactaaactt 120 cagcattccc ttgacactgc ccttcgcaga gcccgcagcg ccccggcagc ggcgatagct 180 gcacgcgtgg cggggcagac ccgcaacatt actgtggacc ccaggctgtt taaaaagcgg 240 cgactccgtt caccccgtgt gctgtttagc acccagcctc cccgtgaagc tgcagacact 300 caggatctgg acttcgaggt cggtggtgct gcccccttca acaggactca caggagcaag 360 cggtcatcat cccatcccat cttccacagg ggcgaattct cggtgtgtga cagtgtcagc 420 gtgtggggttg gggataagac caccgccaca gacatcaagg gcaaggaggt gatggtgttg 480 ggagaggtga acattaacaa cagtgtattc aaacagtact ttttgagac caagtgccgg 540 gacccaaatc ccgttgacag cgggtgccgg ggcattgact caaagcactg gaactcatat 600 tgtaccacga ctcacacctt tgtcaaggcg ctgaccatgg atggcaagca ggctgcctgg 660 cggtttatcc ggatagatac ggcctgtgtg tgtgtgctca gcaggaaggc tgtgagaaga 720 gcctagct cttccaaggc tccacccccc tcactcccat ctcctagtag gctccccgga 780 ccatccgaca cgcctattct gccccagtag 810 <210> 2 <211> 269 <212> PRT <213> Homo sapiens <400> 2 Met Ser Met Leu Phe Tyr Thr Leu Ile Thr Ala Phe Leu Ile Gly Ile 1 5 10 15 Gln Ala Glu Pro His Ser Glu Ser Asn Val Pro Ala Gly His Thr Ile 20 25 30 Pro Gln Ala His Trp Thr Lys Leu Gln His Ser Leu Asp Thr Ala Leu 35 40 45 Arg Arg Ala Arg Ser Ala Pro Ala Ala Ala Ile Ala Ala Arg Val Ala 50 55 60 Gly Gln Thr Arg Asn Ile Thr Val Asp Pro Arg Leu Phe Lys Lys Arg 65 70 75 80 Arg Leu Arg Ser Pro Arg Val Leu Phe Ser Thr Gln Pro Pro Arg Glu 85 90 95 Ala Ala Asp Thr Gln Asp Leu Asp Phe Glu Val Gly Gly Ala Ala Pro 100 105 110 Phe Asn Arg Thr His Arg Ser Lys Arg Ser Ser Ser His Pro Ile Phe 115 120 125 His Arg Gly Glu Phe Ser Val Cys Asp Ser Val Ser Val Trp Val Gly 130 135 140 Asp Lys Thr Thr Ala Thr Asp Ile Lys Gly Lys Glu Val Met Val Leu 145 150 155 160 Gly Glu Val Asn Ile Asn Asn Ser Val Phe Lys Gln Tyr Phe Phe Glu 165 170 175 Thr Lys Cys Arg Asp Pro Asn Pro Val Asp Ser Gly Cys Arg Gly Ile 180 185 190 Asp Ser Lys His Trp Asn Ser Tyr Cys Thr Thr Thr His Thr Phe Val 195 200 205 Lys Ala Leu Thr Met Asp Gly Lys Gln Ala Ala Trp Arg Phe Ile Arg 210 215 220 Ile Asp Thr Ala Cys Val Cys Val Leu Ser Arg Lys Ala Val Arg Arg 225 230 235 240 Ala Ser Ser Ser Ser Lys Ala Pro Pro Pro Ser Leu Pro Ser Pro Ser 245 250 255 Arg Leu Pro Gly Pro Ser Asp Thr Pro Ile Leu Pro Gln 260 265 <210> 3 <211> 148 <212> PRT <213> Homo sapiens <400> 3 Ser Ser Ser His Pro Ile Phe His Arg Gly Glu Phe Ser Val Cys Asp 1 5 10 15 Ser Val Ser Val Trp Val Gly Asp Lys Thr Thr Ala Thr Asp Ile Lys 20 25 30 Gly Lys Glu Val Met Val Leu Gly Glu Val Asn Ile Asn Asn Ser Val 35 40 45 Phe Lys Gln Tyr Phe Phe Glu Thr Lys Cys Arg Asp Pro Asn Pro Val 50 55 60 Asp Ser Gly Cys Arg Gly Ile Asp Ser Lys His Trp Asn Ser Tyr Cys 65 70 75 80 Thr Thr Thr His Thr Phe Val Lys Ala Leu Thr Met Asp Gly Lys Gln 85 90 95 Ala Ala Trp Arg Phe Ile Arg Ile Asp Thr Ala Cys Val Cys Val Leu 100 105 110 Ser Arg Lys Ala Val Arg Arg Ala Ser Ser Ser Ser Lys Ala Pro Pro 115 120 125 Pro Ser Leu Pro Ser Pro Ser Arg Leu Pro Gly Pro Ser Asp Thr Pro 130 135 140 Ile Leu Pro Gln 145 <210> 4 <211> 1052 <212> DNA <213> Homo sapiens <400> 4 agagagcgct gggagccgga ggggagcgca gcgagttttg gccagtggtc gtgcagtcca 60 aggggctgga tggcatgctg gacccaagct cagctcagcg tccggaccca ataacgttt 120 taccaaggga gcagctttct atcctggcca cactgaggtg catagcgtaa tgtccatgtt 180 gttctacact ctgatcacag cttttctgat cggcatacag gcggaaccac actcagagag 240 caatgtccct gcaggacaca ccatccccca agcccactgg actaaacttc agcattccct 300 tgacactgcc cttcgcagag cccgcagcg cccggcagcg gcgatagctg cacgcgtggc 360 ggggcagacc cgcaacatta ctgtggaccc caggctgttt aaaaagcggc gactccgttc 420 accccgtgtg ctgtttagca cccagcctcc ccgtgaagct gcagacactc aggatctgga 480 cttcgaggtc ggtggtgctg cccccttcaa caggactcac aggagcaagc ggtcatcatc 540 ccatcccatc ttccacaggg gcgaattctc ggtgtgtgac agtgtcagcg tgtgggttgg 600 ggataagacc accgccacag acatcaaggg caaggaggtg atggtgttgg gagaggtgaa 660 cattaaaac agtgtattca aacagtactt ttttgagacc aagtgccggg acccaaatcc 720 cgttgacagc gggtgccggg gcattgactc aaagcactgg aactcatatt gtaccacgac 780 tcacaccttt gtcaaggcgc tgaccatgga tggcaagcag gctgcctggc ggtttatccg 840 gatagatacg gcctgtgtgt gtgtgctcag caggaaggct gtgagaagag cctgacctgc 900 cgacacgctc cctccccctg ccccttctac actctcctgg gcccctccct acctcaacct 960 gtaaattat ttaaattata aggactgcat ggtaatttat agtttataca gttttaaaga 1020 atcatatttt attaatttt tggaagcata aa 1052 <210> 5 <211> 241 <212> PRT <213> Homo sapiens <400> 5 Met Ser Met Leu Phe Tyr Thr Leu Ile Thr Ala Phe Leu Ile Gly Ile 1 5 10 15 Gln Ala Glu Pro His Ser Glu Ser Asn Val Pro Ala Gly His Thr Ile 20 25 30 Pro Gln Ala His Trp Thr Lys Leu Gln His Ser Leu Asp Thr Ala Leu 35 40 45 Arg Arg Ala Arg Ser Ala Pro Ala Ala Ala Ile Ala Ala Arg Val Ala 50 55 60 Gly Gln Thr Arg Asn Ile Thr Val Asp Pro Arg Leu Phe Lys Lys Arg 65 70 75 80 Arg Leu Arg Ser Pro Arg Val Leu Phe Ser Thr Gln Pro Pro Arg Glu 85 90 95 Ala Ala Asp Thr Gln Asp Leu Asp Phe Glu Val Gly Gly Ala Ala Pro 100 105 110 Phe Asn Arg Thr His Arg Ser Lys Arg Ser Ser Ser His Pro Ile Phe 115 120 125 His Arg Gly Glu Phe Ser Val Cys Asp Ser Val Ser Val Trp Val Gly 130 135 140 Asp Lys Thr Thr Ala Thr Asp Ile Lys Gly Lys Glu Val Met Val Leu 145 150 155 160 Gly Glu Val Asn Ile Asn Asn Ser Val Phe Lys Gln Tyr Phe Phe Glu 165 170 175 Thr Lys Cys Arg Asp Pro Asn Pro Val Asp Ser Gly Cys Arg Gly Ile 180 185 190 Asp Ser Lys His Trp Asn Ser Tyr Cys Thr Thr Thr His Thr Phe Val 195 200 205 Lys Ala Leu Thr Met Asp Gly Lys Gln Ala Ala Trp Arg Phe Ile Arg 210 215 220 Ile Asp Thr Ala Cys Val Cys Val Leu Ser Arg Lys Ala Val Arg Arg 225 230 235 240 No <210> 6 <211> 1196 <212> DNA <213> Mus musculus <400> 6 cagcacggca gagagcgcct ggagccggag gggagcgcat cgagtgactt tggagctggc 60 cttatatttg gatctcccgg gcagcttttt ggaaactcct agtgaacatg ctgtgcctca 120 agccagtgaa attaggctcc ctggaggtgg gacacgggca gcatggtgga gttttggcct 180 gtggtcgtgc agtccagggg gctggatggc atgctggacc caagctcacc tcagtgtctg 240 ggcccaataa aggttttgcc aaggacgcag cttctatac tggccgcagt gaggtgcata 300 gcgtaatgtc catgttgttc tacactctga tcactgcgtt tttgatcggc gtacaggcag 360 aaccgtacac agatagcaat gtcccagaag gagactctgt ccctgaagcc cactggacta 420 aacttcagca ttcccttgac acagccctcc gcagagcccg cagtgcccct actgcaccaa 480 taggctcccg agtgacaggg cagacccgca acatcactgt agaccccaga ctgtttaaga 540 aacggagact ccactcaccc cgtgtgctgt tcagcaccca gcctccaccc acctcttcag 600 acactctgga tctagacttc caggcccatg gtacaatccc tttcaacagg actcaccgga 660 gcaagcgctc atccacccac ccagtcttcc acatggggga gttctcagtg tgtgacagtg 720 tcagtgtgtg ggttggagat aagaccacag ccacagacat caagggcaag gaggtgacag 780 tgctggccga ggtgaacatt aacaacagtg tattcagaca gtacttttt gagaccaagt 840 gccgagcctc caatcctgtt gagagtgggt gccggggcat cgactccaaa cactggaact 900 catactgcac cacgactcac accttcgtca aggcgttgac aacagatgag aagcaggctg 960 cctggaggtt catccggata gacacagcct gtgtgtgtgt gctcagcagg aaggctacaa 1020 gaagaggctg acttgcctgc agcccccttc cccacctgcc ccctccacac tctcctgggc 1080 ccctccctac ctcagcctgt aattatttt aaattataag gactgcatga taatttatcg 1140 tttatacaat tttaagaca ttttatta aatttcaa gcatcctgta taccga 1196 <210> 7 <211> 307 <212> PRT <213> Muscles <400> 7 Met Leu Cys Leu Lys Pro Val Lys Leu Gly Ser Leu Glu Val Gly His 1 5 10 15 Gly Gln His Gly Gly Val Leu Ala Cys Gly Arg Ala Val Gln Gly Ala 20 25 30 Gly Trp His Ala Gly Pro Lys Leu Thr Ser Val Ser Gly Pro Asn Lys 35 40 45 Gly Phe Ala Lys Asp Ala Ala Phe Tyr Thr Gly Arg Ser Glu Val His 50 55 60 Ser Val Met Ser Met Leu Phe Tyr Thr Leu Ile Thr Ala Phe Leu Ile 65 70 75 80 Gly Val Gln Ala Glu Pro Tyr Thr Asp Ser Asn Val Pro Glu Gly Asp 85 90 95 Ser Val Pro Glu Ala His Trp Thr Lys Leu Gln His Ser Leu Asp Thr 100 105 110 Ala Leu Arg Arg Ala Arg Ser Ala Pro Thr Ala Pro Ile Ala Ala Arg 115 120 125 Val Thr Gly Gln Thr Arg Asn Ile Thr Val Asp Pro Arg Leu Phe Lys 130 135 140 Lys Arg Arg Leu His Ser Pro Arg Val Leu Phe Ser Thr Gln Pro Pro 145 150 155 160 Pro Thr Ser Ser Asp Thr Leu Asp Leu Asp Phe Gln Ala His Gly Thr 165 170 175 Ile Pro Phe Asn Arg Thr His Arg Ser Lys Arg Ser Ser Thr His Pro 180 185 190 Val Phe His Met Gly Glu Phe Ser Val Cys Asp Ser Val Ser Val Trp 195 200 205 Val Gly Asp Lys Thr Thr Ala Thr Asp Ile Lys Gly Lys Glu Val Thr 210 215 220 Val Leu Ala Glu Val Asn Ile Asn Asn Ser Val Phe Arg Gln Tyr Phe 225 230 235 240 Phe Glu Thr Lys Cys Arg Ala Ser Asn Pro Val Glu Ser Gly Cys Arg 245 250 255 Gly Ile Asp Ser Lys His Trp Asn Ser Tyr Cys Thr Thr Thr His Thr 260 265 270 Phe Val Lys Ala Leu Thr Thr Asp Glu Lys Gln Ala Ala Trp Arg Phe 275 280 285 Ile Arg Ile Asp Thr Ala Cys Val Cys Val Leu Ser Arg Lys Ala Thr 290 295 300 Arg Arg Gly 305 <210> 8 <211> 1069 <212> DNA <213> Mus musculus <400> 8 cagcacggca gagagcgcct ggagccggag gggagcgcat cgagttttgg cctgtggtcg 60 tgcagtccag ggggctggat ggcatgctgg acccaagctc acctcagtgt ctgggcccaa 120 taaaggtttt gccaaggacg cagctttcta tactggccgc agtgaggtgc atagcgtaat 180 gtccatgttg ttctacactc tgatcactgc gtttttgatc ggcgtacagg cagaaccgta 240 cacagatagc aatgtcccag aaggagactc tgtccctgaa gcccactgga ctaaacttca 300 gcattccctt gacacagccc tccgcagagc ccgcagtgcc cctactgcac caatagctgc 360 ccgagtgaca gggcagaccc gcaacatcac tgtagacccc agactgttta agaaacggag 420 actccactca ccccgtgtgc tgttcagcac ccagcctcca cccacctctt cagacactct 480 ggatctagac ttccaggccc atggtacaat ccctttcaac aggactcacc ggagcaagcg 540 ctcatccacc cacccagtct tccacatggg ggagttctca gtgtgtgaca gtgtcagtgt 600 gtgggttgga gataagacca cagccacaga catcaagggc aaggaggtga cagtgctggc 660 cgaggtgaac attaacaaca gtgtattcag acagtacttt tttgagacca agtgccgagc 720 ctccaatcct gttgagagtg ggtgccgggg catcgactcc aaacactgga actcatactg 780 caccacgact cacaccttcg tcaaggcgtt gacaacagat gagaagcagg ctgcctggag 840 gttcatccgg atagacacag cctgtgtgtg tgtgctcagc aggaaggcta caagaagagg 900 ctgacttgcc tgcagccccc ttccccacct gccccctcca cactctcctg ggcccctccc 960 tacctcagcc tgtaaattat tttaaattat aaggactgca tgataattta tcgtttatac 1020 aatttaaag acattattta ttaaatttc aaagcatcct gtataccga 1069 <210> 9 <211> 241 <212> PRT <213> Mus musculus <400> 9 Met Ser Met Leu Phe Tyr Thr Leu Ile Thr Ala Phe Leu Ile Gly Val 1 5 10 15 Gln Ala Glu Pro Tyr Thr Asp Ser Asn Val Pro Glu Gly Asp Ser Val 20 25 30 Pro Glu Ala His Trp Thr Lys Leu Gln His Ser Leu Asp Thr Ala Leu 35 40 45 Arg Arg Ala Arg Ser Ala Pro Thr Ala Pro Ile Ala Ala Arg Val Thr 50 55 60 Gly Gln Thr Arg Asn Ile Thr Val Asp Pro Arg Leu Phe Lys Lys Arg 65 70 75 80 Arg Leu His Ser Pro Arg Val Leu Phe Ser Thr Gln Pro Pro Pro Thr 85 90 95 Ser Ser Asp Thr Leu Asp Leu Asp Phe Gln Ala His Gly Thr Ile Pro 100 105 110 Phe Asn Arg Thr His Arg Ser Lys Arg Ser Ser Thr His Pro Val Phe 115 120 125 His Met Gly Glu Phe Ser Val Cys Asp Ser Val Ser Val Trp Val Gly 130 135 140 Asp Lys Thr Thr Ala Thr Asp Ile Lys Gly Lys Glu Val Thr Val Leu 145 150 155 160 Ala Glu Val Asn Ile Asn Asn Ser Val Phe Arg Gln Tyr Phe Phe Glu 165 170 175 Thr Lys Cys Arg Ala Ser Asn Pro Val Glu Ser Gly Cys Arg Gly Ile 180 185 190 Asp Ser Lys His Trp Asn Ser Tyr Cys Thr Thr Thr His Thr Phe Val 195 200 205 Lys Ala Leu Thr Thr Asp Glu Lys Gln Ala Ala Trp Arg Phe Ile Arg 210 215 220 Ile Asp Thr Ala Cys Val Cys Val Leu Ser Arg Lys Ala Thr Arg Arg 225 230 235 240 Gly <210> 10 <211> 151 <212> PRT <213> Homo sapiens <400> 10 Met Gly Gly Thr Trp Ala Ser Lys Glu Pro Leu Arg Pro Arg Cys Arg 1 5 10 15 Pro Ile Asn Ala Thr Leu Ala Val Glu Lys Glu Gly Cys Pro Val Cys 20 25 30 Ile Thr Val Asn Thr Thr Ile Cys Ala Gly Tyr Cys Pro Thr Met Thr 35 40 45 Arg Val Leu Gln Gly Val Leu Pro Ala Leu Pro Gln Val Val Cys Asn 50 55 60 Tyr Arg Asp Val Arg Phe Glu Ser Ile Arg Leu Pro Gly Cys Pro Arg 65 70 75 80 Gly Val Asn Pro Val Val Ser Tyr Ala Val Ala Leu Ser Cys Gln Cys 85 90 95 Ala Leu Cys Arg Arg Ser Thr Thr Asp Cys Gly Gly Pro Lys Asp His 100 105 110 Pro Leu Thr Cys Asp Asp Pro Arg Phe Gln Ala Ser Ser Ser Ser Lys 115 120 125 Ala Pro Pro Pro Ser Leu Pro Ser Pro Ser Arg Leu Pro Gly Pro Ser 130 135 140 Asp Thr Pro Ile Leu Pro Gln 145 150 <210> 11 <211> 163 <212> PRT <213> Homo sapiens <400> 11 Met Ser Lys Gly Leu Leu Leu Leu Leu Leu Leu Ser Met Gly Gly Thr 1 5 10 15 Trp Ala Ser Lys Glu Pro Leu Arg Pro Arg Cys Arg Pro Ile Asn Ala 20 25 30 Thr Leu Ala Val Glu Lys Glu Gly Cys Pro Val Cys Ile Thr Val Asn 35 40 45 Thr Thr Ile Cys Ala Gly Tyr Cys Pro Thr Met Thr Arg Val Leu Gln 50 55 60 Gly Val Leu Pro Ala Leu Pro Gln Val Val Cys Asn Tyr Arg Asp Val 65 70 75 80 Arg Phe Glu Ser Ile Arg Leu Pro Gly Cys Pro Arg Gly Val Asn Pro 85 90 95 Val Val Ser Tyr Ala Val Ala Leu Ser Cys Gln Cys Ala Leu Cys Arg 100 105 110 Arg Ser Thr Thr Asp Cys Gly Gly Pro Lys Asp His Pro Leu Thr Cys 115 120 125 Asp Asp Pro Arg Phe Gln Ala Ser Ser Ser Ser Lys Ala Pro Pro Pro 130 135 140 Ser Leu Pro Ser Pro Ser Arg Leu Pro Gly Pro Ser Asp Thr Pro Ile 145 150 155 160 Leu Pro Gln <210> 12 <211> 165 <212> PRT <213> Homo sapiens <400> 12 Met Glu Met Phe Gln Gly Leu Leu Leu Leu Leu Leu Leu Ser Met Gly 1 5 10 15 Gly Thr Trp Ala Ser Lys Glu Pro Leu Arg Pro Arg Cys Arg Pro Ile 20 25 30 Asn Ala Thr Leu Ala Val Glu Lys Glu Gly Cys Pro Val Cys Ile Thr 35 40 45 Val Asn Thr Thr Ile Cys Ala Gly Tyr Cys Pro Thr Met Thr Arg Val 50 55 60 Leu Gln Gly Val Leu Pro Ala Leu Pro Gln Val Val Cys Asn Tyr Arg 65 70 75 80 Asp Val Arg Phe Glu Ser Ile Arg Leu Pro Gly Cys Pro Arg Gly Val 85 90 95 Asn Pro Val Val Ser Tyr Ala Val Ala Leu Ser Cys Gln Cys Ala Leu 100 105 110 Cys Arg Arg Ser Thr Thr Asp Cys Gly Gly Pro Lys Asp His Pro Leu 115 120 125 Thr Cys Asp Asp Pro Arg Phe Gln Asp Ser Ser Ser Ser Lys Ala Pro 130 135 140 Pro Pro Ser Leu Pro Ser Pro Ser Arg Leu Pro Gly Pro Ser Asp Thr 145 150 155 160 Pro Ile Leu Pro Gln 165 <210> 13 <211> 28 <212> PRT <213> Homo sapiens <400> 13 Ser Ser Ser Lys Ala Pro Pro Pro Ser Leu Pro Ser Pro Ser Arg 1 5 10 15 Leu Pro Gly Pro Ser Asp Thr Pro Ile Leu Pro Gln 20 25 <210> 14 <211> 37 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic first <400> 14 atctcgagca ccatgtccat gttgttctac actctga 37 <210> 15 <211> 39 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic primer <400> 15 tggagccttg gaagagctag aggctcttct cacagcctt 39 <210> 16 <211> 39 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic primer <400> 16 aaggctgtga gaagagcctc tagctcttcc aaggctcca 39 <210> 17 <211> 30 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic primer <400> 17 tttgcggccg cttactactg gggcagaata 30 <210> 18 <211> 6 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic 6xHis tag <400> 18 His His His His His His 1 5 <210> 19 <211> 7 <212> PRT <213> Homo sapiens <400> 19 Ser Ser Ser His Pro Ile Phe 1 5 <210> 20 <211> 6 <212> PRT <213> Homo sapiens <400> 20 Tyr Ala Glu His Lys Ser 1 5

Claims

1. below: (i) a first portion comprising a biologically active nerve growth factor (NGF) polypeptide sequence; (ii) a second portion comprising an additional polypeptide that increases the half-life and maintains biological activity of the NGF polypeptide sequence in the human bloodstream, the second portion comprising an amino acid sequence that is at least 95%, 99% or more identical to SEQ ID NO: 13; and (iii) a third portion comprising a fusion domain that enhances the function and / or stability of the NGF polypeptide sequence in the human bloodstream. and having an in vivo half-life that is at least 2.5 times the in vivo half-life of the NGF polypeptide sequence alone, and wherein the fusion domain in the third portion is selected from polyhistidine, Glu-Glu, glutathione S-transferase (GST), thioredoxin, protein A, protein G, maltose binding protein (MBP), or human serum albumin.

2. The polypeptide of claim 1 , wherein the first portion comprises a full-length NGF polypeptide sequence.

3. The polypeptide of claim 1 , wherein the first portion comprises a fragment having the biological activity of NGF.

4. The polypeptide according to any one of claims 1 to 3, wherein the first portion comprises a human NGF sequence.

5. The polypeptide of claim 4, wherein the human NGF sequence is at least 95% identical to SEQ ID NO:

5.

6. 4. The polypeptide of claim 3, wherein the first portion is capable of binding to at least one binding partner of NGF, and optionally the at least one binding partner of NGF is tropomyosin receptor kinase A (TrkA) or low affinity NGF receptor (LNGFR / p75NTR).

7. The polypeptide of claim 6, wherein the first portion comprises amino acid residues 122 to 241 of SEQ ID NO:

5.

8. The polypeptide of any one of claims 1 to 7, wherein the second portion comprises biologically active human chorionic gonadotropin (HCG).

9. The polypeptide of claim 8, wherein the human chorionic gonadotropin (HCG) comprises an amino acid sequence selected from SEQ ID NOs: 10-12.

10. The polypeptide according to any one of claims 1 to 9, wherein the second portion comprises the carboxy terminal portion (CTP) of HCG.

11. The polypeptide of any one of claims 1 to 10, wherein the first portion is fused to the N-terminus of the second portion.

12. A polypeptide according to any one of claims 1 to 11, comprising an amino acid sequence at least 90%, 95%, 99% or 100% identical to SEQ ID NO: 2 or 3.

13. A polynucleotide encoding the polypeptide according to any one of claims 1 to 12.

14. The polynucleotide of claim 13, comprising a nucleic acid sequence that is at least 95% identical to SEQ ID NO:

1.

15. The polynucleotide of claim 13 comprising the nucleic acid sequence of SEQ ID NO:

1.

16. An expression vector capable of expressing the polypeptide according to any one of claims 1 to 12, and / or an expression vector comprising the polynucleotide according to any one of claims 13 to 15.

17. A host cell comprising the expression vector of claim 16.

18. below: (i) culturing the host cell of claim 17 in a cell culture medium; and (ii) expressing the polypeptide according to any one of claims 1 to 12; The method includes:

19. moreover (iii) purifying the polypeptide according to any one of claims 1 to 12 from the cell culture medium.

20. The method of claim 18, comprising:

20. A composition comprising a polypeptide according to any one of claims 1 to 12, a polynucleotide according to any one of claims 13 to 15, an expression vector according to claim 16, or a host cell according to claim 17.

21. 21. A pharmaceutical composition comprising the composition of claim 20 and a pharma- ceutically acceptable carrier.

22. A pharmaceutical composition for use in the treatment of a disease or disorder associated with a deficiency and / or defect in nerve growth factor (NGF), comprising a therapeutically effective amount of a polypeptide according to any one of claims 1 to 12, a polynucleotide according to any one of claims 13 to 15, a composition according to claim 20, or a pharmaceutical composition according to claim 21.

23. 23. The pharmaceutical composition of claim 22, further comprising an additional drug and / or therapy for treating the disease or disorder administered to the subject.

24. 24. The pharmaceutical composition according to claim 22 or 23, wherein the disease or disorder is a neurological disorder.

25. 25. The pharmaceutical composition of claim 24, wherein the neurological disorder is amyotrophic lateral sclerosis (Lou Gehrig's disease), Alzheimer's disease, Bell's palsy, dementia, Down's syndrome, epilepsy, Huntington's chorea, Meniere's disease, multiple sclerosis, nerve hearing loss, stroke, hypoxic-ischemic encephalopathy, cerebral palsy, paralysis, Parkinson's disease, peripheral neuropathy, optic neuropathy or spinal muscular atrophy.

26. 26. The pharmaceutical composition of claim 25, wherein the neuropathy is a peripheral neuropathy, and the peripheral neuropathy is a polyneuropathy or a mononeuropathy.

27. 26. The pharmaceutical composition of claim 25, wherein the neuropathy is an optic neuropathy, the optic neuropathy being an anterior or posterior ocular degenerative disease, a chronic allergic inflammatory disorder of the ocular surface, a traumatic optic neuropathy, glaucoma, neurotrophic keratopathy, herpes simplex keratitis, or corneal healing.

28. The pharmaceutical composition according to any one of claims 24 to 27, wherein the neuropathy is caused by necrosis or loss of central neurons, peripheral neurons, motor neurons, or sensory neurons, trauma, renal dysfunction, injury, surgery, ischemia, infection, metabolic disease, nutritional deficiency, malignant tumor, toxic substance, or chemotherapy.

29. The pharmaceutical composition according to any one of claims 22 to 28, wherein the subject is a mammal.

30. A pharmaceutical composition for promoting neuronal growth and / or proliferation in a subject in need thereof, comprising an effective amount of a polypeptide according to any one of claims 1 to 12, a composition according to claim 20, or a pharmaceutical composition according to claim 21.

31. The pharmaceutical composition of claim 30, wherein the subject is a mammal.

Images